Lesch-Nyhan Syndrome

Mendelian MONDO:0010298 Pathograph 32 Inborn error of purine metabolism X-linked recessive disorder Neurodevelopmental disorder

Lesch-Nyhan syndrome is an X-linked recessive disorder of purine metabolism caused by deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT1), leading to overproduction of uric acid, severe neurological dysfunction including dystonia, choreoathetosis, intellectual disability, and a striking compulsive self-injurious behavior phenotype.

Ask OpenScientist

Ask a research question about Lesch-Nyhan Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
5
Pathophys.
20
Phenotypes
32
Pathograph
1
Genes
5
Treatments
1
Deep Research
👪

Inheritance

1
X-linked recessive HP:0001419
X-linked recessive inheritance Penetrance: COMPLETE
Show evidence (2 references)
PMID:18067674 SUPPORT Human Clinical
"Inheritance of HPRT deficiency is X-linked recessive, thus males are generally affected and heterozygous female are carriers (usually asymptomatic)."
Confirms X-linked recessive inheritance with males affected and carrier females typically asymptomatic.
ORPHA:510 SUPPORT
"X-linked recessive"
Orphanet confirms X-linked recessive inheritance pattern.
⚙

Pathophysiology

5
HPRT1 Enzyme Deficiency and Purine Overproduction
Loss of HPRT activity abolishes the purine salvage pathway, preventing recycling of hypoxanthine and guanine to IMP and GMP. This leads to accumulation of hypoxanthine, which is oxidized to uric acid by xanthine oxidase. Additionally, phosphoribosyl pyrophosphate (PRPP) accumulates due to lack of consumption by HPRT, driving de novo purine synthesis and further increasing uric acid production.
HPRT1 link
Purine nucleotide salvage link ∅ ABSENT Uric acid overproduction link ↑ INCREASED
hypoxanthine phosphoribosyltransferase activity link guanine phosphoribosyltransferase activity link
Downstream
Hyperuricemia and Gout Massive uric acid overproduction leads to crystal deposition in joints, kidneys, and urinary tract.
Basal Ganglia Dopaminergic Dysfunction Purine metabolic disruption leads to dopaminergic dysfunction through incompletely understood mechanisms.
Mitochondrial Energy Metabolism Disruption HPRT1 deficiency disrupts mitochondrial energy metabolism through complex I inhibition, though the precise intermediary steps are not fully elucidated.
ZMP Accumulation and Stress Signaling Accelerated de novo purine synthesis leads to accumulation of the intermediate ZMP/AICAR under physiological folate conditions.
Elevated serum uric acid HPRT deficiency causes uric acid overproduction detectable as hyperuricemia.
Elevated urinary uric acid HPRT deficiency causes uric acid overproduction detectable as hyperuricosuria.
Absent HPRT enzyme activity Loss-of-function HPRT1 variants cause absent or near-absent HPRT enzyme activity.
Megaloblastic anemia HPRT deficiency is associated with megaloblastic anemia, but the precise intermediate mechanism is not specified in cached evidence.
Show evidence (3 references)
PMID:32310539 SUPPORT Human Clinical
"The enzyme is responsible for recycling purines by converting guanine and hypoxanthine into guanosine monophosphate and inosine monophosphate, respectively. Lack of the enzyme causes an increase in guanine and hypoxanthine, which eventually is converted into uric acid."
Describes the metabolic basis of purine overproduction and uric acid accumulation.
PMID:22198833 SUPPORT Human Clinical
"The pathogenesis of overproduction of uric acid in HPRT deficiency is well-understood, and treatments are available to control it."
Confirms that uric acid overproduction mechanism is well-established.
DOI:10.1186/s10020-023-00774-8 SUPPORT In Vitro
"To compensate this deficiency, there is an acceleration of the de novo purine biosynthetic pathway."
Demonstrates accelerated de novo purine synthesis in LND fibroblasts as a compensatory mechanism for HPRT deficiency.
Hyperuricemia and Gout
Massively elevated serum uric acid leads to monosodium urate crystal deposition in joints (gout), urinary tract (nephrolithiasis), and kidneys (urate nephropathy), potentially causing renal failure if untreated.
Downstream
Hyperuricemia HPRT-deficiency-driven uric acid overproduction causes hyperuricemia.
Gout Uric acid overproduction leads to monosodium urate crystal arthropathy.
Nephrolithiasis Urate excess causes uric acid nephrolithiasis in the urinary tract.
Hematuria Urate lithiasis and urinary tract crystal passage can cause hematuria.
Renal insufficiency Uric acid crystal nephropathy and nephrolithiasis can progress to renal insufficiency.
Show evidence (2 references)
PMID:22198833 SUPPORT Human Clinical
"All of these phenotypes are associated with marked overproduction of uric acid and related problems such as hyperuricemia, urate nephrolithiasis, tophi, and gout."
Describes the range of uric acid-related complications in HPRT deficiency.
PMID:18067674 SUPPORT Human Clinical
"Uric acid overproduction is present inall HPRT-deficient patients and is associated with lithiasis and gout."
Confirms universal uric acid overproduction across all HPRT deficiency phenotypes.
Basal Ganglia Dopaminergic Dysfunction
HPRT deficiency leads to profound dopaminergic dysfunction in the basal ganglia, with loss of dopaminergic neurotransmitter phenotype and reduced dopamine content in the striatum. This dopamine deficit underlies the movement disorder (dystonia, choreoathetosis) and is hypothesized to contribute to the self-injurious behavior through disrupted reward circuitry. Importantly, this reflects loss of dopaminergic phenotype rather than neuronal degeneration.
Dopaminergic neuron link ⚠ ABNORMAL Medium spiny neuron link
Dopamine biosynthesis link ↓ DECREASED
Basal ganglia link
Downstream
Dystonia Basal ganglia dopaminergic dysfunction contributes to the severe movement disorder dominated by generalized dystonia.
Choreoathetosis Basal ganglia dysfunction contributes to the hyperkinetic movement disorder that includes choreoathetosis.
Self-injurious behavior Basal ganglia dysfunction is implicated in the hallmark compulsive self-injury phenotype.
Intellectual disability Basal-ganglia and associated cortical circuit dysfunction contributes to the cognitive component of the LND neurobehavioral phenotype.
Global developmental delay HPRT-related neurodevelopmental abnormalities include early global developmental delay, with the exact intermediate steps still incompletely resolved.
Hemiballismus Basal-ganglia motor circuit dysfunction contributes to ballismus within the extrapyramidal movement-disorder spectrum.
Spasticity HPRT deficiency can include spasticity as part of its neurological disability, but the precise intermediate mechanism is not resolved in cached evidence.
Dysarthria Dystonia and spasticity affecting orofacial motor control can produce dysarthria.
Dysphagia Dystonia and spasticity affecting oropharyngeal motor control can produce dysphagia.
Hemiplegia/hemiparesis Hemiplegia or hemiparesis is recorded as a very frequent motor phenotype, but the precise causal intermediate is not specified in cached evidence.
Show evidence (4 references)
PMID:10760551 SUPPORT Human Clinical
"neurochemical studies have demonstrated 60-90% reductions in the dopamine content of the basal ganglia"
Quantifies the severe dopamine loss in the basal ganglia of LND patients.
PMID:24891139 SUPPORT Human Clinical
"neurons of the substantia nigra from the LND cases showed reduced melanization and reduced immunoreactivity for tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis"
Demonstrates loss of dopaminergic phenotype in midbrain neurons without neurodegeneration.
PMID:10760551 SUPPORT Human Clinical
"These findings support the proposal that many of the neurobehavioral features of LND might be related to dysfunction of the basal ganglia."
Supports the central role of basal ganglia dysfunction in LND neurobehavioral features.
+ 1 more reference
Mitochondrial Energy Metabolism Disruption
HPRT1 deficiency inhibits complex I-dependent mitochondrial respiration, resulting in increased mitochondrial NADH levels, reduction of mitochondrial membrane potential, and increased rate of reactive oxygen species (ROS) production. However, this increased ROS production does not induce oxidative stress or deplete endogenous glutathione, suggesting that disruption of mitochondrial energy metabolism rather than oxidative stress is the potential trigger of brain pathology in LNS.
Mitochondrial complex I respiration link ↓ DECREASED Reactive oxygen species production link ↑ INCREASED
Show evidence (2 references)
DOI:10.1007/s12035-023-03266-2 SUPPORT Model Organism
"We found that HPRT1 deficiency inhibits complex I-dependent mitochondrial respiration resulting in increased levels of mitochondrial NADH, reduction of the mitochondrial membrane potential, and increased rate of reactive oxygen species (ROS) production in mitochondria and cytosol."
Demonstrates that HPRT1 deficiency directly impairs mitochondrial complex I respiration and increases ROS in murine neurons.
DOI:10.1007/s12035-023-03266-2 SUPPORT Model Organism
"Thus, disruption of mitochondrial energy metabolism but not oxidative stress could play a role of potential trigger of brain pathology in LNS."
Concludes that mitochondrial energy disruption rather than oxidative stress is the key pathological mechanism.
ZMP Accumulation and Stress Signaling
Under physiological folate conditions, LND fibroblasts accumulate 5-aminoimidazole-4-carboxamide riboside 5'-monophosphate (ZMP/AICAR), an intermediate of the de novo purine biosynthetic pathway. ZMP accumulation activates AMP-activated protein kinase (AMPK) and inhibits adenylosuccinate lyase (ADSL). LND fibroblasts also show metabolic adaptations including higher glycolytic capacity, increased expression of the folate carrier SLC19A1, decreased mitochondrial potential, and reduced cell migration. These alterations can be reversed with high levels of folic acid. Note: these findings are based on in vitro fibroblast data and CNS relevance has not been established in vivo.
De novo purine nucleotide biosynthesis link ↑ INCREASED
Show evidence (2 references)
DOI:10.1186/s10020-023-00774-8 SUPPORT In Vitro
"LND fibroblasts maintained with Plasmax-PV show metabolic adaptations such a higher glycolytic capacity, increased expression of the folate carrier SCL19A1, and functional alterations such a decreased mitochondrial potential and reduced cell migration compared to controls."
Demonstrates multiple cellular alterations in LND fibroblasts under physiological culture conditions, including metabolic and functional changes.
DOI:10.1186/s10020-023-00774-8 SUPPORT In Vitro
"These alterations can be reverted with high levels of folic acid, suggesting that folic acid supplements might be a potential treatment for LND."
Shows that folic acid supplementation can reverse the cellular alterations caused by ZMP accumulation in LND fibroblasts.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Lesch-Nyhan Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

20
Blood 1
Megaloblastic anemia OCCASIONAL Megaloblastic anemia (HP:0001889)
Show evidence (2 references)
PMID:18067674 SUPPORT Human Clinical
"Megaloblastic anaemia is also associated with the disease."
Confirms megaloblastic anemia as an associated feature.
ORPHA:510 SUPPORT
"HP:0001903 | Anemia | Frequent (79-30%)"
Orphanet classifies anemia as frequent (79-30%) in Lesch-Nyhan syndrome. Megaloblastic anemia is a more specific subtype.
Digestive 1
Dysphagia Dysphagia (HP:0002015)
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"Physical rehabilitation, including management of dysarthria and dysphagia, special devices to enable hand control, appropriate walking aids, and a programme of posture management to prevent deformities are recommended."
Dysphagia is listed alongside dysarthria as requiring rehabilitation management in LNS.
Genitourinary 4
Nephrolithiasis FREQUENT Uric acid nephrolithiasis (HP:0000791)
Show evidence (1 reference)
PMID:22198833 SUPPORT Human Clinical
"All of these phenotypes are associated with marked overproduction of uric acid and related problems such as hyperuricemia, urate nephrolithiasis, tophi, and gout."
Lists urate nephrolithiasis as a complication of uric acid overproduction.
Renal insufficiency FREQUENT Renal insufficiency (HP:0000083)
Show evidence (2 references)
PMID:8156315 SUPPORT Human Clinical
"Acute renal failure secondary to crystal nephropathy and tophaceous gout are unusual presenting features of this rare condition."
Documents acute renal failure from crystal nephropathy as a presenting feature of Lesch-Nyhan syndrome.
ORPHA:510 SUPPORT
"HP:0000083 | Renal insufficiency | Frequent (79-30%)"
Orphanet classifies renal insufficiency as frequent (79-30%) in Lesch-Nyhan syndrome.
Hematuria FREQUENT Hematuria (HP:0000790)
Show evidence (2 references)
ORPHA:510 SUPPORT
"HP:0000790 | Hematuria | Frequent (79-30%)"
Orphanet classifies hematuria as frequent (79-30%) in Lesch-Nyhan syndrome, secondary to uric acid crystalluria.
PMID:18067674 SUPPORT Human Clinical
"Uric acid overproduction is present inall HPRT-deficient patients and is associated with lithiasis and gout."
Uric acid lithiasis is universal in HPRT deficiency, and hematuria is a common consequence of urinary tract crystal formation.
Acute kidney injury Acute kidney injury (HP:0001919)
Show evidence (1 reference)
PMID:8156315 SUPPORT Human Clinical
"Acute renal failure secondary to crystal nephropathy and tophaceous gout are unusual presenting features of this rare condition."
Case report documents acute renal failure from crystal nephropathy as an unusual presenting feature of Lesch-Nyhan syndrome.
Metabolism 1
Hyperuricemia OBLIGATE Hyperuricemia (HP:0002149)
Show evidence (2 references)
PMID:18067674 SUPPORT Human Clinical
"Uric acid overproduction is present inall HPRT-deficient patients and is associated with lithiasis and gout."
Confirms universal uric acid overproduction in all HPRT-deficient patients.
ORPHA:510 SUPPORT
"HP:0002149 | Hyperuricemia | Very frequent (99-80%)"
Orphanet classifies hyperuricemia as very frequent (99-80%) in Lesch-Nyhan syndrome.
Musculoskeletal 3
Spasticity VERY_FREQUENT Spasticity (HP:0001257)
Show evidence (2 references)
PMID:18067674 SUPPORT Human Clinical
"Spasticity, when present, and dystonia can be managed with benzodiazepines and gamma-aminobutyric acid inhibitors such as baclofen."
Mentions spasticity as a feature requiring management.
ORPHA:510 SUPPORT
"HP:0001257 | Spasticity | Very frequent (99-80%)"
Orphanet classifies spasticity as very frequent (99-80%) in Lesch-Nyhan syndrome.
Gout VERY_FREQUENT Gout (HP:0001997)
Show evidence (2 references)
PMID:19259384 SUPPORT Human Clinical
"LND is characterized by overproduction of uric acid, leading to gouty arthritis and nephrolithiasis."
Confirms gout as a clinical feature of LND.
ORPHA:510 SUPPORT
"HP:0001997 | Gout | Very frequent (99-80%)"
Orphanet classifies gout as very frequent (99-80%) in Lesch-Nyhan syndrome.
Hypertonia Hypertonia (HP:0001276)
Show evidence (1 reference)
PMID:22198833 SUPPORT Human Clinical
"Poorly controlled movements along with increased muscle tone also emerge during the first year of life."
Review of the LND phenotypic spectrum documents increased muscle tone (hypertonia) emerging in the first year of life.
Nervous System 6
Self-injurious behavior OBLIGATE Self-injurious behavior (HP:0100716)
Show evidence (2 references)
PMID:22198833 SUPPORT Human Clinical
"The most severe phenotype is known as Lesch-Nyhan disease, in which the phenotype also includes severe motor handicap, intellectual disability, and self-injurious behavior."
Identifies self-injurious behavior as a defining feature of classic Lesch-Nyhan disease.
PMID:27920633 SUPPORT Human Clinical
"Symptoms of LNS include dystonia, gout, intellectual disability, and self-mutilation."
Confirms self-mutilation as a core symptom.
Dystonia OBLIGATE Dystonia (HP:0001332)
Show evidence (2 references)
PMID:18067674 SUPPORT Human Clinical
"Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit, and self-injurious behaviour."
Lists dystonia as a primary neurological manifestation.
PMID:24891139 SUPPORT Human Clinical
"a characteristic neurobehavioral phenotype that includes a movement disorder dominated by generalized dystonia, intellectual disability, and recurrent self-injurious behavior."
Characterizes the movement disorder as dominated by generalized dystonia.
Choreoathetosis VERY_FREQUENT Choreoathetosis (HP:0001266)
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit, and self-injurious behaviour."
Lists choreoathetosis among the neurological manifestations.
Intellectual disability OBLIGATE Intellectual disability (HP:0001249)
Show evidence (2 references)
PMID:22198833 SUPPORT Human Clinical
"The most severe phenotype is known as Lesch-Nyhan disease, in which the phenotype also includes severe motor handicap, intellectual disability, and self-injurious behavior."
Lists intellectual disability as part of the classic LND phenotype.
ORPHA:510 SUPPORT
"HP:0002342 | Intellectual disability, moderate | Very frequent (99-80%)"
Orphanet classifies moderate intellectual disability as very frequent (99-80%), though severity ranges from mild to moderate depending on the individual.
Global developmental delay OBLIGATE Global developmental delay (HP:0001263)
Show evidence (1 reference)
PMID:32310539 SUPPORT Human Clinical
"The characteristics defining the disease are hyperuricemia, neurodevelopmental abnormalities with global developmental delay, involuntary movements, and self-injurious behavior."
Lists global developmental delay as a defining characteristic.
Dysarthria Dysarthria (HP:0001260)
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"Physical rehabilitation, including management of dysarthria and dysphagia, special devices to enable hand control, appropriate walking aids, and a programme of posture management to prevent deformities are recommended."
Dysarthria is listed as a feature requiring management in LNS patients.
Other 4
Hemiballismus Hemiballismus (HP:0100248)
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit, and self-injurious behaviour."
Ballismus is listed as a primary neurological manifestation of HPRT deficiency.
Hemiplegia/hemiparesis VERY_FREQUENT Hemiplegia/hemiparesis (HP:0004374)
Show evidence (1 reference)
ORPHA:510 SUPPORT
"HP:0004374 | Hemiplegia/hemiparesis | Very frequent (99-80%)"
Orphanet classifies hemiplegia/hemiparesis as very frequent (99-80%) in Lesch-Nyhan syndrome, reflecting pyramidal tract involvement.
Urate tophus Urate tophus (HP:0033073)
Show evidence (2 references)
PMID:22198833 SUPPORT Human Clinical
"All of these phenotypes are associated with marked overproduction of uric acid and related problems such as hyperuricemia, urate nephrolithiasis, tophi, and gout."
Review lists tophi among the uric-acid overproduction complications across the HPRT-deficiency phenotypic spectrum.
PMID:8156315 SUPPORT Human Clinical
"Acute renal failure secondary to crystal nephropathy and tophaceous gout are unusual presenting features of this rare condition."
Case report documents tophaceous gout as a presenting feature of Lesch-Nyhan syndrome.
Short attention span Short attention span (HP:0000736)
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit, and self-injurious behaviour."
Orphanet review lists attention deficit among the neurological manifestations of HPRT deficiency.
🧬

Genetic Associations

1
HPRT1 mutations (Loss-of-function mutations)
Show evidence (4 references)
PMID:18067674 SUPPORT Human Clinical
"Human HPRT is encoded by a single structural gene on the long arm of the X chromosome at Xq26. To date, more than 300 disease-associated mutations in the HPRT1 gene have been identified."
Documents HPRT1 as the causative gene with over 300 known mutations.
PMID:32310539 SUPPORT Human Clinical
"Lesch Nyhan syndrome is an inborn disorder caused by a deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT) enzyme, an enzyme of the purine salvage pathway."
Confirms HPRT enzyme deficiency as the cause of Lesch-Nyhan syndrome.
ORPHA:510 SUPPORT
"HPRT1 | hypoxanthine phosphoribosyltransferase 1 | hgnc:5157 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet confirms HPRT1 as the causative gene with loss-of-function mechanism.
+ 1 more reference
💊

Treatments

5
Allopurinol
Action: Allopurinol therapy Ontology label: Pharmacotherapy NCIT:C15986
Agent: allopurinol ↗
Xanthine oxidase inhibitor that reduces uric acid production. Controls hyperuricemia, gout, and prevents urate nephropathy. Does not affect neurological or behavioral features.
Mechanism Target:
INHIBITS Hyperuricemia and Gout — Allopurinol reduces uric acid overproduction and thereby treats the urate-complication branch of the pathograph.
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"Uric acid overproduction can be managed by allopurinol treatment."
Clinical review supports allopurinol treatment for the uric-acid overproduction mechanism.
Target Phenotypes: Hyperuricemia ↗ Gout ↗ Uric acid nephrolithiasis ↗
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"Uric acid overproduction can be managed by allopurinol treatment."
Confirms allopurinol as the standard treatment for uric acid overproduction.
Behavioral Management and Physical Restraints
Action: Behavioral management Ontology label: supportive care MAXO:0000950
Physical restraints, protective equipment (arm splints, helmets, lip guards), and environmental modifications are essential to prevent self-mutilation. Patients often request their own restraints.
Target Phenotypes: Self-injurious behavior ↗
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"Self-injurious behaviour must be managed by a combination of physical restraints, behavioural and pharmaceutical treatments."
Describes the multimodal approach to managing self-injurious behavior.
Baclofen
Action: Pharmacotherapy NCIT:C15986
Agent: baclofen ↗
Pharmacologic treatment used to manage spasticity and dystonia in Lesch-Nyhan syndrome.
Target Phenotypes: Spasticity ↗ Dystonia ↗
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"Spasticity, when present, and dystonia can be managed with benzodiazepines and gamma-aminobutyric acid inhibitors such as baclofen."
Supports baclofen as pharmacologic management for spasticity and dystonia in Lesch-Nyhan syndrome.
Physical Rehabilitation
Action: Physical rehabilitation Ontology label: physical therapy MAXO:0000011
Management of dysarthria, dysphagia, walking aids, hand control devices, and posture management to prevent deformities.
Target Phenotypes: Dysarthria ↗ Dysphagia ↗
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"Physical rehabilitation, including management of dysarthria and dysphagia, special devices to enable hand control, appropriate walking aids, and a programme of posture management to prevent deformities are recommended."
Describes the comprehensive rehabilitation approach.
Deep Brain Stimulation
Action: Deep brain stimulation Ontology label: deep brain stimulation MAXO:0000943
Deep brain stimulation (DBS) targeting the globus pallidus internus (GPi) has been explored as a treatment for medically resistant dystonia and self-injurious behavior in Lesch-Nyhan syndrome. DBS may reduce the severity of dystonia and decrease self-injurious episodes in selected patients who do not respond to pharmacological and behavioral interventions.
Target Phenotypes: Dystonia ↗ Self-injurious behavior ↗
Show evidence (1 reference)
PMID:36694014 SUPPORT Human Clinical
"DBS improved dystonia of the LNS to varying degrees. All the included cases achieved partial or complete control of self-injurious behavior (SIB). Overall, DBS is a promising treatment for both motor and behavior disorders of LNS patients, but the results reported thus far have varied widely,..."
Systematic review of 12 LNS patients showing DBS improved dystonia and achieved partial or complete control of self-injurious behavior.
🔬

Biochemical Markers

3
Elevated serum uric acid (INCREASED)
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"Uric acid overproduction is present inall HPRT-deficient patients and is associated with lithiasis and gout."
Confirms universal uric acid overproduction in all HPRT-deficient patients.
Elevated urinary uric acid (INCREASED)
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"The diagnosis is based on clinical and biochemical findings (hyperuricemia and hyperuricosuria associated with psychomotor delay)"
Confirms hyperuricosuria as a diagnostic biochemical finding.
Absent HPRT enzyme activity (DECREASED)
Show evidence (1 reference)
PMID:18067674 SUPPORT Human Clinical
"enzymatic (HPRT activity determination in haemolysate, intact erythrocytes or fibroblasts) and molecular tests"
Confirms HPRT enzyme activity testing in erythrocyte lysates as a diagnostic method.
{ }

Source YAML

click to show 
name: Lesch-Nyhan Syndrome
creation_date: "2026-03-22T07:38:41Z"
updated_date: "2026-05-19T09:30:58Z"
category: Mendelian
description: >-
  Lesch-Nyhan syndrome is an X-linked recessive disorder of purine metabolism caused by
  deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT1), leading to
  overproduction of uric acid, severe neurological dysfunction including dystonia,
  choreoathetosis, intellectual disability, and a striking compulsive self-injurious
  behavior phenotype.
disease_term:
  preferred_term: Lesch-Nyhan syndrome
  term:
    id: MONDO:0010298
    label: Lesch-Nyhan syndrome
parents:
- Inborn error of purine metabolism
- X-linked recessive disorder
- Neurodevelopmental disorder
synonyms:
- LNS
- HPRT deficiency
- hypoxanthine-guanine phosphoribosyltransferase deficiency
- Lesch-Nyhan disease
prevalence:
- population: Canada
  percentage: 1 in 380,000 live births
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence is estimated at 1/380,000 live births in Canada, and 1/235,000 live births in Spain."
    explanation: Provides population-based prevalence estimates for HPRT deficiency.
- population: Spain
  percentage: 1 in 235,000 live births
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence is estimated at 1/380,000 live births in Canada, and 1/235,000 live births in Spain."
    explanation: Provides population-based prevalence estimates for HPRT deficiency.
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "1-9 / 1 000 000 | Spain | Point prevalence | PMID:18067674"
    explanation: Orphanet epidemiology confirms Spanish prevalence in the 1-9 per million range.
- population: United Kingdom
  percentage: 1 in 2,000,000 (prevalence); 1.8 per 1,000,000 live births (incidence)
  evidence:
  - reference: PMID:21126241
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-one live people with LND were identified in the UK in 2008, giving a prevalence of 1 in 2 million people. Over the 20 years of study, there was a mean incidence rate of 0.18 per 100 000 live births, range 0 to 0.5."
    explanation: First UK population study of LND providing prevalence and incidence data over 20 years.
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "1-9 / 1 000 000 | United Kingdom | Prevalence at birth | PMID:21152085,PMID:21126241"
    explanation: Orphanet epidemiology confirms UK prevalence in the 1-9 per million range.
- population: Europe
  percentage: 1-9 per 1,000,000
  evidence:
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "1-9 / 1 000 000 | Europe | Point prevalence | ORPHANET"
    explanation: Orphanet expert estimate of European point prevalence.
inheritance:
- name: X-linked recessive
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  penetrance: COMPLETE
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Inheritance of HPRT deficiency is X-linked recessive, thus males are generally affected and heterozygous female are carriers (usually asymptomatic)."
    explanation: Confirms X-linked recessive inheritance with males affected and carrier females typically asymptomatic.
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "X-linked recessive"
    explanation: Orphanet confirms X-linked recessive inheritance pattern.
genetic:
- name: HPRT1 mutations
  gene_term:
    preferred_term: HPRT1
    term:
      id: hgnc:5157
      label: HPRT1
  presence: PRESENT
  association: Loss-of-function mutations
  variants:
  - name: HPRT1 loss-of-function (classic LNS)
    description: >-
      Complete loss of HPRT enzyme activity (<1.5% of normal) from null,
      frameshift, nonsense, or splice-site mutations. Over 300 disease-associated
      mutations identified across the gene.
    clinical_significance: PATHOGENIC
  - name: HPRT1 hypomorphic variants (Kelley-Seegmiller syndrome)
    description: >-
      Partial HPRT deficiency (1.5-8% residual activity) from missense mutations
      that reduce but do not abolish enzyme function. Presents with hyperuricemia
      and gout but without the neurological or behavioral features of classic LNS.
    clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Human HPRT is encoded by a single structural gene on the long arm of the X chromosome at Xq26. To date, more than 300 disease-associated mutations in the HPRT1 gene have been identified."
    explanation: Documents HPRT1 as the causative gene with over 300 known mutations.
  - reference: PMID:32310539
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lesch Nyhan syndrome is an inborn disorder caused by a deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT) enzyme, an enzyme of the purine salvage pathway."
    explanation: Confirms HPRT enzyme deficiency as the cause of Lesch-Nyhan syndrome.
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "HPRT1 | hypoxanthine phosphoribosyltransferase 1 | hgnc:5157 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet confirms HPRT1 as the causative gene with loss-of-function mechanism.
  - reference: CGGV:assertion_f60022bb-5679-4766-ac72-2ddfd0b752ee-2022-07-07T220000.000Z
    reference_title: "HPRT1 / Lesch-Nyhan syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HPRT1 | HGNC:5157 | Lesch-Nyhan syndrome | MONDO:0010298 | XL | Definitive"
    explanation: ClinGen classifies the HPRT1-Lesch-Nyhan syndrome gene-disease relationship as definitive with X-linked inheritance.
pathophysiology:
- name: HPRT1 Enzyme Deficiency and Purine Overproduction
  description: >-
    Loss of HPRT activity abolishes the purine salvage pathway, preventing recycling
    of hypoxanthine and guanine to IMP and GMP. This leads to accumulation of
    hypoxanthine, which is oxidized to uric acid by xanthine oxidase. Additionally,
    phosphoribosyl pyrophosphate (PRPP) accumulates due to lack of consumption by
    HPRT, driving de novo purine synthesis and further increasing uric acid production.
  genes:
  - preferred_term: HPRT1
    term:
      id: hgnc:5157
      label: HPRT1
  biological_processes:
  - preferred_term: Purine nucleotide salvage
    term:
      id: GO:0032261
      label: purine nucleotide salvage
    modifier: ABSENT
  - preferred_term: Uric acid overproduction
    term:
      id: GO:0006145
      label: purine nucleobase catabolic process
    modifier: INCREASED
  molecular_functions:
  - preferred_term: hypoxanthine phosphoribosyltransferase activity
    term:
      id: GO:0004422
      label: hypoxanthine phosphoribosyltransferase activity
  - preferred_term: guanine phosphoribosyltransferase activity
    term:
      id: GO:0052657
      label: guanine phosphoribosyltransferase activity
  chemical_entities:
  - preferred_term: hypoxanthine
    term:
      id: CHEBI:17368
      label: hypoxanthine
    modifier: INCREASED
  - preferred_term: guanine
    term:
      id: CHEBI:16235
      label: guanine
    modifier: INCREASED
  - preferred_term: uric acid
    term:
      id: CHEBI:27226
      label: uric acid
    modifier: INCREASED
  evidence:
  - reference: PMID:32310539
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The enzyme is responsible for recycling purines by converting guanine and hypoxanthine into guanosine monophosphate and inosine monophosphate, respectively. Lack of the enzyme causes an increase in guanine and hypoxanthine, which eventually is converted into uric acid."
    explanation: Describes the metabolic basis of purine overproduction and uric acid accumulation.
  - reference: PMID:22198833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pathogenesis of overproduction of uric acid in HPRT deficiency is well-understood, and treatments are available to control it."
    explanation: Confirms that uric acid overproduction mechanism is well-established.
  - reference: DOI:10.1186/s10020-023-00774-8
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "To compensate this deficiency, there is an acceleration of the de novo purine biosynthetic pathway."
    explanation: Demonstrates accelerated de novo purine synthesis in LND fibroblasts as a compensatory mechanism for HPRT deficiency.
  downstream:
  - target: Hyperuricemia and Gout
    description: >-
      Massive uric acid overproduction leads to crystal deposition in joints, kidneys,
      and urinary tract.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22198833
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "All of these phenotypes are associated with marked overproduction of uric acid and related problems such as hyperuricemia, urate nephrolithiasis, tophi, and gout."
      explanation: Directly links purine overproduction to uric acid-related complications.
  - target: Basal Ganglia Dopaminergic Dysfunction
    description: >-
      Purine metabolic disruption leads to dopaminergic dysfunction through
      incompletely understood mechanisms.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:22198833
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The pathogenesis of the neurobehavioral problems is less well-understood, and effective treatments for them are lacking."
      explanation: Acknowledges the causal link from purine metabolism to neurobehavioral features while noting the mechanism is incompletely understood.
  - target: Mitochondrial Energy Metabolism Disruption
    description: >-
      HPRT1 deficiency disrupts mitochondrial energy metabolism through
      complex I inhibition, though the precise intermediary steps are not
      fully elucidated.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: DOI:10.1007/s12035-023-03266-2
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "HPRT1 deficiency inhibits complex I-dependent mitochondrial respiration resulting in increased levels of mitochondrial NADH, reduction of the mitochondrial membrane potential, and increased rate of reactive oxygen species (ROS) production in mitochondria and cytosol."
      explanation: Demonstrates that HPRT1 deficiency leads to mitochondrial respiration defects in murine neurons.
  - target: ZMP Accumulation and Stress Signaling
    description: >-
      Accelerated de novo purine synthesis leads to accumulation of the
      intermediate ZMP/AICAR under physiological folate conditions.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.1186/s10020-023-00774-8
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "To compensate this deficiency, there is an acceleration of the de novo purine biosynthetic pathway."
      explanation: Links the compensatory acceleration of de novo purine synthesis to downstream ZMP accumulation.
  - target: Elevated serum uric acid
    description: HPRT deficiency causes uric acid overproduction detectable as hyperuricemia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:18067674
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The diagnosis is based on clinical and biochemical findings (hyperuricemia and hyperuricosuria associated with psychomotor delay)"
      explanation: Clinical review evidence identifies hyperuricemia as a diagnostic biochemical finding in HPRT deficiency.
    - reference: PMID:22198833
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The overproduction of uric acid is present even at birth and can be detected by hyperuricemia or increased urinary uric acid excretion."
      explanation: Review evidence directly connects HPRT-deficiency uric acid overproduction to elevated serum uric acid.
  - target: Elevated urinary uric acid
    description: HPRT deficiency causes uric acid overproduction detectable as hyperuricosuria.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:18067674
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The diagnosis is based on clinical and biochemical findings (hyperuricemia and hyperuricosuria associated with psychomotor delay)"
      explanation: Clinical review evidence identifies hyperuricosuria as a diagnostic biochemical finding in HPRT deficiency.
    - reference: PMID:22198833
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The overproduction of uric acid is present even at birth and can be detected by hyperuricemia or increased urinary uric acid excretion."
      explanation: Review evidence directly connects HPRT-deficiency uric acid overproduction to increased urinary uric acid excretion.
  - target: Absent HPRT enzyme activity
    description: Loss-of-function HPRT1 variants cause absent or near-absent HPRT enzyme activity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:18067674
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        Deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT)
        activity is an inborn error of purine metabolism associated with uric
        acid overproduction and a continuum spectrum of neurological
        manifestations depending on the degree of the enzymatic deficiency.
      explanation: Clinical review evidence directly identifies HPRT activity deficiency as the enzymatic basis of the disorder.
  - target: Megaloblastic anemia
    description: HPRT deficiency is associated with megaloblastic anemia, but the precise intermediate mechanism is not specified in cached evidence.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:18067674
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Megaloblastic anaemia is also associated with the disease."
      explanation: Clinical review evidence supports megaloblastic anemia as an associated LNS feature.
- name: Hyperuricemia and Gout
  description: >-
    Massively elevated serum uric acid leads to monosodium urate crystal deposition
    in joints (gout), urinary tract (nephrolithiasis), and kidneys (urate nephropathy),
    potentially causing renal failure if untreated.
  evidence:
  - reference: PMID:22198833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All of these phenotypes are associated with marked overproduction of uric acid and related problems such as hyperuricemia, urate nephrolithiasis, tophi, and gout."
    explanation: Describes the range of uric acid-related complications in HPRT deficiency.
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Uric acid overproduction is present inall HPRT-deficient patients and is associated with lithiasis and gout."
    explanation: Confirms universal uric acid overproduction across all HPRT deficiency phenotypes.
  downstream:
  - target: Hyperuricemia
    description: HPRT-deficiency-driven uric acid overproduction causes hyperuricemia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22198833
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "All of these phenotypes are associated with marked overproduction of uric acid and related problems such as hyperuricemia, urate nephrolithiasis, tophi, and gout."
      explanation: Directly lists hyperuricemia among the uric-acid overproduction complications of HPRT deficiency.
  - target: Gout
    description: Uric acid overproduction leads to monosodium urate crystal arthropathy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19259384
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "LND is characterized by overproduction of uric acid, leading to gouty arthritis and nephrolithiasis."
      explanation: Directly links uric acid overproduction to gouty arthritis.
  - target: Nephrolithiasis
    description: Urate excess causes uric acid nephrolithiasis in the urinary tract.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19259384
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "LND is characterized by overproduction of uric acid, leading to gouty arthritis and nephrolithiasis."
      explanation: Directly links uric acid overproduction to nephrolithiasis.
  - target: Hematuria
    description: Urate lithiasis and urinary tract crystal passage can cause hematuria.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - uric acid lithiasis and urinary tract crystal passage
    evidence:
    - reference: ORPHA:510
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000790 | Hematuria | Frequent (79-30%)"
      explanation: Orphanet classifies hematuria as frequent in Lesch-Nyhan syndrome.
    - reference: PMID:18067674
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Uric acid overproduction is present inall HPRT-deficient patients and is associated with lithiasis and gout."
      explanation: Clinical review evidence links universal uric acid overproduction to lithiasis, the intermediate used for hematuria.
  - target: Renal insufficiency
    description: Uric acid crystal nephropathy and nephrolithiasis can progress to renal insufficiency.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - uric acid crystal nephropathy
    - urate nephrolithiasis
    evidence:
    - reference: PMID:8156315
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Acute renal failure secondary to crystal nephropathy and tophaceous gout are unusual presenting features of this rare condition."
      explanation: Case-report evidence supports renal failure from crystal nephropathy in Lesch-Nyhan syndrome.
    - reference: ORPHA:510
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000083 | Renal insufficiency | Frequent (79-30%)"
      explanation: Orphanet classifies renal insufficiency as frequent in Lesch-Nyhan syndrome.
- name: Basal Ganglia Dopaminergic Dysfunction
  description: >-
    HPRT deficiency leads to profound dopaminergic dysfunction in the basal ganglia,
    with loss of dopaminergic neurotransmitter phenotype and reduced dopamine content
    in the striatum. This dopamine deficit underlies the movement disorder (dystonia,
    choreoathetosis) and is hypothesized to contribute to the self-injurious
    behavior through disrupted reward circuitry. Importantly, this reflects loss of
    dopaminergic phenotype rather than neuronal degeneration.
  cell_types:
  - preferred_term: Dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
    modifier: ABNORMAL
  - preferred_term: Medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: Dopamine biosynthesis
    term:
      id: GO:0042416
      label: dopamine biosynthetic process
    modifier: DECREASED
  locations:
  - preferred_term: Basal ganglia
    term:
      id: UBERON:0002420
      label: basal ganglion
  evidence:
  - reference: PMID:10760551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "neurochemical studies have demonstrated 60-90% reductions in the dopamine content of the basal ganglia"
    explanation: Quantifies the severe dopamine loss in the basal ganglia of LND patients.
  - reference: PMID:24891139
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "neurons of the substantia nigra from the LND cases showed reduced melanization and reduced immunoreactivity for tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis"
    explanation: Demonstrates loss of dopaminergic phenotype in midbrain neurons without neurodegeneration.
  - reference: PMID:10760551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings support the proposal that many of the neurobehavioral features of LND might be related to dysfunction of the basal ganglia."
    explanation: Supports the central role of basal ganglia dysfunction in LND neurobehavioral features.
  - reference: DOI:10.1007/s12035-023-03266-2
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "One of the hallmarks of LNS is maximal expression of HPRT in the central nervous system with the highest activity of this enzyme in the midbrain and basal ganglia."
    explanation: Demonstrates that HPRT is maximally expressed in the midbrain and basal ganglia, explaining why these regions are most affected in LNS.
  downstream:
  - target: Dystonia
    description: Basal ganglia dopaminergic dysfunction contributes to the severe movement disorder dominated by generalized dystonia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:10760551
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These findings support the proposal that many of the neurobehavioral features of LND might be related to dysfunction of the basal ganglia."
      explanation: Human neurochemical evidence supports a basal-ganglia contribution to LND neurobehavioral manifestations.
    - reference: PMID:24891139
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "a characteristic neurobehavioral phenotype that includes a movement disorder dominated by generalized dystonia, intellectual disability, and recurrent self-injurious behavior."
      explanation: Human neuropathology study connects the LND neurobehavioral phenotype with generalized dystonia, intellectual disability, and self-injury.
    - reference: PMID:24891139
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the major motor problem is dystonia, a movement disorder that has been linked with early developmental dysfunction of dopamine pathways and the motor circuit of the basal ganglia involving the putamen and motor cortex."
      explanation: Review text in a human neuropathology study specifically links dystonia to developmental dysfunction of basal-ganglia dopamine pathways.
  - target: Choreoathetosis
    description: Basal ganglia dysfunction contributes to the hyperkinetic movement disorder that includes choreoathetosis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:10760551
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Affected individuals have severe motor disability described by prominent extrapyramidal features that are characteristic of dysfunction of the motor circuits of the basal ganglia."
      explanation: Human review links the extrapyramidal motor disability of LND to dysfunction of basal-ganglia motor circuits.
    - reference: PMID:18067674
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit, and self-injurious behaviour."
      explanation: Clinical review lists choreoathetosis within the neurological manifestations of HPRT deficiency.
  - target: Self-injurious behavior
    description: Basal ganglia dysfunction is implicated in the hallmark compulsive self-injury phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:10760551
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These findings support the proposal that many of the neurobehavioral features of LND might be related to dysfunction of the basal ganglia."
      explanation: Human neurochemical evidence supports a basal-ganglia contribution to LND neurobehavioral features including self-injury.
    - reference: PMID:24891139
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The behavioral phenotype, in particular self-injurious behavior, has been linked with early brain dopamine loss in the limbic circuit involving the ventral striatum and orbitofrontal cortex."
      explanation: Review text in a human neuropathology study specifically links self-injurious behavior to early dopamine loss in a basal-ganglia limbic circuit.
  - target: Intellectual disability
    description: Basal-ganglia and associated cortical circuit dysfunction contributes to the cognitive component of the LND neurobehavioral phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24891139
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Lesch–Nyhan disease (LND) is an inherited disorder with a characteristic neurobehavioral phenotype that includes a movement disorder dominated by generalized dystonia, intellectual disability, and recurrent self-injurious behavior."
      explanation: Human neuropathology review evidence includes intellectual disability within the LND neurobehavioral phenotype.
    - reference: PMID:24891139
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The pattern of cognitive deficits shows prominent problems with attention and executive functions, defects that have been proposed to result from dysfunction of pathways involving the caudate and dorsolateral prefrontal cortex."
      explanation: This supports a basal-ganglia-associated cortical circuit contribution to cognitive deficits.
  - target: Global developmental delay
    description: HPRT-related neurodevelopmental abnormalities include early global developmental delay, with the exact intermediate steps still incompletely resolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:32310539
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The characteristics defining the disease are hyperuricemia, neurodevelopmental abnormalities with global developmental delay, involuntary movements, and self-injurious behavior."
      explanation: Clinical case-report review evidence identifies global developmental delay as part of the LNS neurodevelopmental phenotype.
    - reference: PMID:22198833
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The classic form of LND evolves in a very characteristic fashion, with the majority of patients presenting with neurodevelopmental delay in the first year of life"
      explanation: Review evidence supports early neurodevelopmental delay as part of classic LND.
  - target: Hemiballismus
    description: Basal-ganglia motor circuit dysfunction contributes to ballismus within the extrapyramidal movement-disorder spectrum.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - extrapyramidal basal-ganglia motor circuit dysfunction
    evidence:
    - reference: PMID:10760551
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Affected individuals have severe motor disability described by prominent extrapyramidal features that are characteristic of dysfunction of the motor circuits of the basal ganglia."
      explanation: Human review evidence links extrapyramidal motor disability to basal-ganglia motor circuit dysfunction.
    - reference: PMID:18067674
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit, and self-injurious behaviour."
      explanation: Clinical review evidence lists ballismus among the neurological manifestations of HPRT deficiency.
  - target: Spasticity
    description: HPRT deficiency can include spasticity as part of its neurological disability, but the precise intermediate mechanism is not resolved in cached evidence.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:32310539
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        and hyperuricemia with neurological disability (enzyme activity 1.5 to
        2% with hyperuricemia symptoms and neurological symptoms like dystonia,
        choreoathetosis, spasticity, intellectual disability).
      explanation: Clinical review evidence includes spasticity among neurological symptoms of HPRT deficiency.
    - reference: ORPHA:510
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001257 | Spasticity | Very frequent (99-80%)"
      explanation: Orphanet classifies spasticity as very frequent in Lesch-Nyhan syndrome.
  - target: Dysarthria
    description: Dystonia and spasticity affecting orofacial motor control can produce dysarthria.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - orofacial motor impairment from dystonia and spasticity
    evidence:
    - reference: PMID:18067674
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Physical rehabilitation, including management of dysarthria and dysphagia, special devices to enable hand control, appropriate walking aids, and a programme of posture management to prevent deformities are recommended."
      explanation: Clinical review evidence identifies dysarthria as an LNS manifestation requiring rehabilitation management.
  - target: Dysphagia
    description: Dystonia and spasticity affecting oropharyngeal motor control can produce dysphagia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - oropharyngeal motor impairment from dystonia and spasticity
    evidence:
    - reference: PMID:18067674
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Physical rehabilitation, including management of dysarthria and dysphagia, special devices to enable hand control, appropriate walking aids, and a programme of posture management to prevent deformities are recommended."
      explanation: Clinical review evidence identifies dysphagia as an LNS manifestation requiring rehabilitation management.
  - target: Hemiplegia/hemiparesis
    description: Hemiplegia or hemiparesis is recorded as a very frequent motor phenotype, but the precise causal intermediate is not specified in cached evidence.
    causal_link_type: UNKNOWN
    evidence:
    - reference: ORPHA:510
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0004374 | Hemiplegia/hemiparesis | Very frequent (99-80%)"
      explanation: Orphanet classifies hemiplegia or hemiparesis as very frequent in Lesch-Nyhan syndrome.
- name: Mitochondrial Energy Metabolism Disruption
  description: >-
    HPRT1 deficiency inhibits complex I-dependent mitochondrial respiration,
    resulting in increased mitochondrial NADH levels, reduction of mitochondrial
    membrane potential, and increased rate of reactive oxygen species (ROS)
    production. However, this increased ROS production does not induce oxidative
    stress or deplete endogenous glutathione, suggesting that disruption of
    mitochondrial energy metabolism rather than oxidative stress is the potential
    trigger of brain pathology in LNS.
  biological_processes:
  - preferred_term: Mitochondrial complex I respiration
    term:
      id: GO:0006120
      label: mitochondrial electron transport, NADH to ubiquinone
    modifier: DECREASED
  - preferred_term: Reactive oxygen species production
    term:
      id: GO:0072593
      label: reactive oxygen species metabolic process
    modifier: INCREASED
  evidence:
  - reference: DOI:10.1007/s12035-023-03266-2
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We found that HPRT1 deficiency inhibits complex I-dependent mitochondrial respiration resulting in increased levels of mitochondrial NADH, reduction of the mitochondrial membrane potential, and increased rate of reactive oxygen species (ROS) production in mitochondria and cytosol."
    explanation: Demonstrates that HPRT1 deficiency directly impairs mitochondrial complex I respiration and increases ROS in murine neurons.
  - reference: DOI:10.1007/s12035-023-03266-2
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Thus, disruption of mitochondrial energy metabolism but not oxidative stress could play a role of potential trigger of brain pathology in LNS."
    explanation: Concludes that mitochondrial energy disruption rather than oxidative stress is the key pathological mechanism.
- name: ZMP Accumulation and Stress Signaling
  description: >-
    Under physiological folate conditions, LND fibroblasts accumulate
    5-aminoimidazole-4-carboxamide riboside 5'-monophosphate (ZMP/AICAR), an
    intermediate of the de novo purine biosynthetic pathway. ZMP accumulation
    activates AMP-activated protein kinase (AMPK) and inhibits adenylosuccinate
    lyase (ADSL). LND fibroblasts also show metabolic adaptations including higher
    glycolytic capacity, increased expression of the folate carrier SLC19A1,
    decreased mitochondrial potential, and reduced cell migration. These
    alterations can be reversed with high levels of folic acid. Note: these
    findings are based on in vitro fibroblast data and CNS relevance has not
    been established in vivo.
  biological_processes:
  - preferred_term: De novo purine nucleotide biosynthesis
    term:
      id: GO:0006164
      label: purine nucleotide biosynthetic process
    modifier: INCREASED
  evidence:
  - reference: DOI:10.1186/s10020-023-00774-8
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "LND fibroblasts maintained with Plasmax-PV show metabolic adaptations such a higher glycolytic capacity, increased expression of the folate carrier SCL19A1, and functional alterations such a decreased mitochondrial potential and reduced cell migration compared to controls."
    explanation: Demonstrates multiple cellular alterations in LND fibroblasts under physiological culture conditions, including metabolic and functional changes.
  - reference: DOI:10.1186/s10020-023-00774-8
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These alterations can be reverted with high levels of folic acid, suggesting that folic acid supplements might be a potential treatment for LND."
    explanation: Shows that folic acid supplementation can reverse the cellular alterations caused by ZMP accumulation in LND fibroblasts.
phenotypes:
- category: Neurological
  name: Self-injurious behavior
  frequency: OBLIGATE
  description: >-
    Compulsive self-mutilation is the hallmark behavioral feature, typically emerging
    between ages 2-4 years. Includes lip and finger biting severe enough to cause
    tissue loss. Patients are often distressed by their own behavior and may request
    physical restraints.
  phenotype_term:
    preferred_term: Self-injurious behavior
    term:
      id: HP:0100716
      label: Self-injurious behavior
  evidence:
  - reference: PMID:22198833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most severe phenotype is known as Lesch-Nyhan disease, in which the phenotype also includes severe motor handicap, intellectual disability, and self-injurious behavior."
    explanation: Identifies self-injurious behavior as a defining feature of classic Lesch-Nyhan disease.
  - reference: PMID:27920633
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms of LNS include dystonia, gout, intellectual disability, and self-mutilation."
    explanation: Confirms self-mutilation as a core symptom.
- category: Neurological
  name: Dystonia
  frequency: OBLIGATE
  description: >-
    Generalized dystonia is a prominent feature, contributing to significant motor
    disability. Onset typically in the first year of life.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit, and self-injurious behaviour."
    explanation: Lists dystonia as a primary neurological manifestation.
  - reference: PMID:24891139
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a characteristic neurobehavioral phenotype that includes a movement disorder dominated by generalized dystonia, intellectual disability, and recurrent self-injurious behavior."
    explanation: Characterizes the movement disorder as dominated by generalized dystonia.
- category: Neurological
  name: Choreoathetosis
  frequency: VERY_FREQUENT
  description: >-
    Involuntary choreiform and athetoid movements affecting limbs and trunk.
  phenotype_term:
    preferred_term: Choreoathetosis
    term:
      id: HP:0001266
      label: Choreoathetosis
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit, and self-injurious behaviour."
    explanation: Lists choreoathetosis among the neurological manifestations.
- category: Neurological
  name: Spasticity
  frequency: VERY_FREQUENT
  description: >-
    Upper motor neuron spasticity contributing to pyramidal signs and motor
    impairment.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spasticity, when present, and dystonia can be managed with benzodiazepines and gamma-aminobutyric acid inhibitors such as baclofen."
    explanation: Mentions spasticity as a feature requiring management.
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "HP:0001257 | Spasticity | Very frequent (99-80%)"
    explanation: Orphanet classifies spasticity as very frequent (99-80%) in Lesch-Nyhan syndrome.
- category: Neurological
  name: Intellectual disability
  frequency: OBLIGATE
  description: >-
    Moderate to severe intellectual disability is present in classic LNS.
    Cognitive function may be underestimated due to severe motor and behavioral
    limitations that interfere with testing.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:22198833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most severe phenotype is known as Lesch-Nyhan disease, in which the phenotype also includes severe motor handicap, intellectual disability, and self-injurious behavior."
    explanation: Lists intellectual disability as part of the classic LND phenotype.
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "HP:0002342 | Intellectual disability, moderate | Very frequent (99-80%)"
    explanation: Orphanet classifies moderate intellectual disability as very frequent (99-80%), though severity ranges from mild to moderate depending on the individual.
- category: Neurological
  name: Global developmental delay
  frequency: OBLIGATE
  description: >-
    Delayed motor and cognitive milestones, typically noted by 3-6 months of age
    with hypotonia and delayed sitting.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:32310539
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The characteristics defining the disease are hyperuricemia, neurodevelopmental abnormalities with global developmental delay, involuntary movements, and self-injurious behavior."
    explanation: Lists global developmental delay as a defining characteristic.
- category: Metabolic
  name: Hyperuricemia
  frequency: OBLIGATE
  description: >-
    Markedly elevated serum uric acid levels, often exceeding 10 mg/dL, resulting
    from both increased de novo purine synthesis and failure of purine salvage.
  phenotype_term:
    preferred_term: Hyperuricemia
    term:
      id: HP:0002149
      label: Hyperuricemia
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Uric acid overproduction is present inall HPRT-deficient patients and is associated with lithiasis and gout."
    explanation: Confirms universal uric acid overproduction in all HPRT-deficient patients.
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "HP:0002149 | Hyperuricemia | Very frequent (99-80%)"
    explanation: Orphanet classifies hyperuricemia as very frequent (99-80%) in Lesch-Nyhan syndrome.
- category: Metabolic
  name: Gout
  frequency: VERY_FREQUENT
  description: >-
    Urate crystal arthropathy may develop, particularly if hyperuricemia is
    untreated. Allopurinol controls this manifestation effectively.
  phenotype_term:
    preferred_term: Gout
    term:
      id: HP:0001997
      label: Gout
  evidence:
  - reference: PMID:19259384
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LND is characterized by overproduction of uric acid, leading to gouty arthritis and nephrolithiasis."
    explanation: Confirms gout as a clinical feature of LND.
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "HP:0001997 | Gout | Very frequent (99-80%)"
    explanation: Orphanet classifies gout as very frequent (99-80%) in Lesch-Nyhan syndrome.
- category: Renal
  name: Nephrolithiasis
  frequency: FREQUENT
  description: >-
    Uric acid nephrolithiasis may be the presenting feature, sometimes detected
    as orange crystalluria in infancy.
  phenotype_term:
    preferred_term: Uric acid nephrolithiasis
    term:
      id: HP:0000791
      label: Uric acid nephrolithiasis
  evidence:
  - reference: PMID:22198833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All of these phenotypes are associated with marked overproduction of uric acid and related problems such as hyperuricemia, urate nephrolithiasis, tophi, and gout."
    explanation: Lists urate nephrolithiasis as a complication of uric acid overproduction.
- category: Renal
  name: Renal insufficiency
  frequency: FREQUENT
  description: >-
    Progressive renal insufficiency from urate nephropathy may develop if
    hyperuricemia is untreated.
  phenotype_term:
    preferred_term: Renal insufficiency
    term:
      id: HP:0000083
      label: Renal insufficiency
  evidence:
  - reference: PMID:8156315
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acute renal failure secondary to crystal nephropathy and tophaceous gout are unusual presenting features of this rare condition."
    explanation: Documents acute renal failure from crystal nephropathy as a presenting feature of Lesch-Nyhan syndrome.
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "HP:0000083 | Renal insufficiency | Frequent (79-30%)"
    explanation: Orphanet classifies renal insufficiency as frequent (79-30%) in Lesch-Nyhan syndrome.
- category: Hematologic
  name: Megaloblastic anemia
  frequency: OCCASIONAL
  description: >-
    Megaloblastic erythropoiesis can occur due to impaired purine nucleotide
    availability for DNA synthesis.
  phenotype_term:
    preferred_term: Megaloblastic anemia
    term:
      id: HP:0001889
      label: Megaloblastic anemia
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Megaloblastic anaemia is also associated with the disease."
    explanation: Confirms megaloblastic anemia as an associated feature.
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "HP:0001903 | Anemia | Frequent (79-30%)"
    explanation: Orphanet classifies anemia as frequent (79-30%) in Lesch-Nyhan syndrome. Megaloblastic anemia is a more specific subtype.
- category: Renal
  name: Hematuria
  frequency: FREQUENT
  description: >-
    Hematuria may occur secondary to uric acid crystal formation and passage
    through the urinary tract, or from urate nephrolithiasis.
  phenotype_term:
    preferred_term: Hematuria
    term:
      id: HP:0000790
      label: Hematuria
  evidence:
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "HP:0000790 | Hematuria | Frequent (79-30%)"
    explanation: Orphanet classifies hematuria as frequent (79-30%) in Lesch-Nyhan syndrome, secondary to uric acid crystalluria.
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Uric acid overproduction is present inall HPRT-deficient patients and is associated with lithiasis and gout."
    explanation: Uric acid lithiasis is universal in HPRT deficiency, and hematuria is a common consequence of urinary tract crystal formation.
- category: Neurological
  name: Dysarthria
  description: >-
    Speech articulation disorder resulting from dystonia and spasticity
    affecting the orofacial musculature. Most patients have severely impaired
    or absent speech.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical rehabilitation, including management of dysarthria and dysphagia, special devices to enable hand control, appropriate walking aids, and a programme of posture management to prevent deformities are recommended."
    explanation: Dysarthria is listed as a feature requiring management in LNS patients.
- category: Neurological
  name: Dysphagia
  description: >-
    Swallowing difficulty resulting from dystonia and spasticity affecting the
    oropharyngeal musculature. May necessitate modified diet consistency or
    gastrostomy feeding.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical rehabilitation, including management of dysarthria and dysphagia, special devices to enable hand control, appropriate walking aids, and a programme of posture management to prevent deformities are recommended."
    explanation: Dysphagia is listed alongside dysarthria as requiring rehabilitation management in LNS.
- category: Neurological
  name: Hemiballismus
  description: >-
    Involuntary flinging movements of the extremities, typically
    affecting proximal limb muscles. Part of the hyperkinetic movement
    disorder spectrum in LNS alongside dystonia and choreoathetosis.
  phenotype_term:
    preferred_term: Hemiballismus
    term:
      id: HP:0100248
      label: Hemiballismus
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit, and self-injurious behaviour."
    explanation: Ballismus is listed as a primary neurological manifestation of HPRT deficiency.
- category: Neurological
  name: Hemiplegia/hemiparesis
  frequency: VERY_FREQUENT
  description: >-
    Unilateral motor weakness reflecting pyramidal tract involvement from
    upper motor neuron dysfunction. May be asymmetric and contribute to
    functional impairment alongside the extrapyramidal movement disorder.
  phenotype_term:
    preferred_term: Hemiplegia/hemiparesis
    term:
      id: HP:0004374
      label: Hemiplegia/hemiparesis
  evidence:
  - reference: ORPHA:510
    supports: SUPPORT
    snippet: "HP:0004374 | Hemiplegia/hemiparesis | Very frequent (99-80%)"
    explanation: Orphanet classifies hemiplegia/hemiparesis as very frequent (99-80%) in Lesch-Nyhan syndrome, reflecting pyramidal tract involvement.
- category: Neurological
  name: Hypertonia
  description: >-
    Increased muscle tone emerges during the first year of life alongside the
    poorly controlled movements, contributing to the early motor disability of
    classic Lesch-Nyhan disease.
  phenotype_term:
    preferred_term: Hypertonia
    term:
      id: HP:0001276
      label: Hypertonia
  evidence:
  - reference: PMID:22198833
    reference_title: "Update on the phenotypic spectrum of Lesch-Nyhan disease and its attenuated variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Poorly controlled movements along with increased muscle tone also emerge during the first year of life."
    explanation: Review of the LND phenotypic spectrum documents increased muscle tone (hypertonia) emerging in the first year of life.
- category: Metabolic
  name: Urate tophus
  description: >-
    Deposition of monosodium urate crystals forming tophi, a consequence of the
    massive uric acid overproduction that characterizes HPRT deficiency.
  phenotype_term:
    preferred_term: Urate tophus
    term:
      id: HP:0033073
      label: Urate tophus
  evidence:
  - reference: PMID:22198833
    reference_title: "Update on the phenotypic spectrum of Lesch-Nyhan disease and its attenuated variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All of these phenotypes are associated with marked overproduction of uric acid and related problems such as hyperuricemia, urate nephrolithiasis, tophi, and gout."
    explanation: Review lists tophi among the uric-acid overproduction complications across the HPRT-deficiency phenotypic spectrum.
  - reference: PMID:8156315
    reference_title: "Lesch-Nyhan syndrome presenting with renal insufficiency in infancy and transient neonatal hypothyroidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acute renal failure secondary to crystal nephropathy and tophaceous gout are unusual presenting features of this rare condition."
    explanation: Case report documents tophaceous gout as a presenting feature of Lesch-Nyhan syndrome.
- category: Renal
  name: Acute kidney injury
  description: >-
    Acute renal failure can occur secondary to uric acid crystal nephropathy,
    occasionally as a presenting feature in infancy.
  phenotype_term:
    preferred_term: Acute kidney injury
    term:
      id: HP:0001919
      label: Acute kidney injury
  evidence:
  - reference: PMID:8156315
    reference_title: "Lesch-Nyhan syndrome presenting with renal insufficiency in infancy and transient neonatal hypothyroidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acute renal failure secondary to crystal nephropathy and tophaceous gout are unusual presenting features of this rare condition."
    explanation: Case report documents acute renal failure from crystal nephropathy as an unusual presenting feature of Lesch-Nyhan syndrome.
- category: Neurological
  name: Short attention span
  description: >-
    Attention deficit is recognised among the cognitive manifestations of HPRT
    deficiency, distinct from the global intellectual disability.
  phenotype_term:
    preferred_term: Attention deficit
    term:
      id: HP:0000736
      label: Short attention span
  evidence:
  - reference: PMID:18067674
    reference_title: "Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit, and self-injurious behaviour."
    explanation: Orphanet review lists attention deficit among the neurological manifestations of HPRT deficiency.
biochemical:
- name: Elevated serum uric acid
  presence: INCREASED
  notes: >-
    Serum uric acid is typically markedly elevated (>10 mg/dL in affected males),
    reflecting the massive overproduction of purines.
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Uric acid overproduction is present inall HPRT-deficient patients and is associated with lithiasis and gout."
    explanation: Confirms universal uric acid overproduction in all HPRT-deficient patients.
- name: Elevated urinary uric acid
  presence: INCREASED
  notes: >-
    Uric acid to creatinine ratio in urine is greatly elevated, often the earliest
    biochemical clue in infancy.
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis is based on clinical and biochemical findings (hyperuricemia and hyperuricosuria associated with psychomotor delay)"
    explanation: Confirms hyperuricosuria as a diagnostic biochemical finding.
- name: Absent HPRT enzyme activity
  presence: DECREASED
  notes: >-
    HPRT enzyme activity in erythrocyte lysates is absent or near-absent (<1.5% of normal)
    in classic LNS.
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "enzymatic (HPRT activity determination in haemolysate, intact erythrocytes or fibroblasts) and molecular tests"
    explanation: Confirms HPRT enzyme activity testing in erythrocyte lysates as a diagnostic method.
treatments:
- name: Allopurinol
  description: >-
    Xanthine oxidase inhibitor that reduces uric acid production. Controls
    hyperuricemia, gout, and prevents urate nephropathy. Does not affect
    neurological or behavioral features.
  treatment_term:
    preferred_term: Allopurinol therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: allopurinol
      term:
        id: CHEBI:40279
        label: allopurinol
  target_phenotypes:
  - preferred_term: Hyperuricemia
    term:
      id: HP:0002149
      label: Hyperuricemia
  - preferred_term: Gout
    term:
      id: HP:0001997
      label: Gout
  - preferred_term: Uric acid nephrolithiasis
    term:
      id: HP:0000791
      label: Uric acid nephrolithiasis
  target_mechanisms:
  - target: Hyperuricemia and Gout
    treatment_effect: INHIBITS
    description: Allopurinol reduces uric acid overproduction and thereby treats the urate-complication branch of the pathograph.
    evidence:
    - reference: PMID:18067674
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Uric acid overproduction can be managed by allopurinol treatment."
      explanation: Clinical review supports allopurinol treatment for the uric-acid overproduction mechanism.
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Uric acid overproduction can be managed by allopurinol treatment."
    explanation: Confirms allopurinol as the standard treatment for uric acid overproduction.
- name: Behavioral Management and Physical Restraints
  description: >-
    Physical restraints, protective equipment (arm splints, helmets, lip guards),
    and environmental modifications are essential to prevent self-mutilation.
    Patients often request their own restraints.
  treatment_term:
    preferred_term: Behavioral management
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Self-injurious behavior
    term:
      id: HP:0100716
      label: Self-injurious behavior
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Self-injurious behaviour must be managed by a combination of physical restraints, behavioural and pharmaceutical treatments."
    explanation: Describes the multimodal approach to managing self-injurious behavior.
- name: Baclofen
  description: >-
    Pharmacologic treatment used to manage spasticity and dystonia in
    Lesch-Nyhan syndrome.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: baclofen
      term:
        id: CHEBI:2972
        label: baclofen
  target_phenotypes:
  - preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  - preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spasticity, when present, and dystonia can be managed with benzodiazepines and gamma-aminobutyric acid inhibitors such as baclofen."
    explanation: Supports baclofen as pharmacologic management for spasticity and dystonia in Lesch-Nyhan syndrome.
- name: Physical Rehabilitation
  description: >-
    Management of dysarthria, dysphagia, walking aids, hand control devices,
    and posture management to prevent deformities.
  treatment_term:
    preferred_term: Physical rehabilitation
    term:
      id: MAXO:0000011
      label: physical therapy
  target_phenotypes:
  - preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  - preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:18067674
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical rehabilitation, including management of dysarthria and dysphagia, special devices to enable hand control, appropriate walking aids, and a programme of posture management to prevent deformities are recommended."
    explanation: Describes the comprehensive rehabilitation approach.
- name: Deep Brain Stimulation
  description: >-
    Deep brain stimulation (DBS) targeting the globus pallidus internus (GPi) has
    been explored as a treatment for medically resistant dystonia and self-injurious
    behavior in Lesch-Nyhan syndrome. DBS may reduce the severity of dystonia and
    decrease self-injurious episodes in selected patients who do not respond to
    pharmacological and behavioral interventions.
  treatment_term:
    preferred_term: Deep brain stimulation
    term:
      id: MAXO:0000943
      label: deep brain stimulation
  target_phenotypes:
  - preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  - preferred_term: Self-injurious behavior
    term:
      id: HP:0100716
      label: Self-injurious behavior
  evidence:
  - reference: PMID:36694014
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DBS improved dystonia of the LNS to varying degrees. All the included cases achieved partial or complete control of self-injurious behavior (SIB). Overall, DBS is a promising treatment for both motor and behavior disorders of LNS patients, but the results reported thus far have varied widely, especially for motor outcomes."
    explanation: Systematic review of 12 LNS patients showing DBS improved dystonia and achieved partial or complete control of self-injurious behavior.
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Pathophysiology Research Template
Edison Scientific Literature 45 citations 2026-03-22T10:20:38.079921

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Lesch-Nyhan Syndrome
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Lesch-Nyhan Syndrome. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Lesch–Nyhan syndrome (LNS) pathophysiology research report (molecular/cellular mechanisms)

Disease identifiers and scope

  • Disease name: Lesch–Nyhan syndrome / Lesch–Nyhan disease (classic severe phenotype of HPRT deficiency)
  • Category: Mendelian (X-linked)
  • Core causal gene: HPRT1 (HGNC: 5157) encoding hypoxanthine-guanine phosphoribosyltransferase (HGPRT/HPRT) (camici2023inbornerrorsof pages 7-8)
  • Note on MONDO ID: Not retrievable from the provided tool evidence; report proceeds with gene/protein-grounded identifiers.

Executive summary (current understanding)

Lesch–Nyhan syndrome is caused by severe loss of HPRT1/HGPRT activity, disrupting the purine salvage pathway and leading to (i) systemic overproduction of uric acid (hyperuricemia/hyperuricuria) and (ii) a characteristic neurobehavioral phenotype dominated by dystonia and compulsive self-injury that is not corrected by urate-lowering therapy (camici2023inbornerrorsof pages 8-9, bairddaniel2023singleelectrodedeepbrain pages 1-2). Contemporary work (2023–2024) increasingly emphasizes that brain vulnerability reflects a combination of (a) developmental disruption of midbrain dopaminergic circuitry and basal ganglia network function, and (b) bioenergetic/metabolic stress (mitochondrial complex I effects; purine pool imbalance; PRPP limitation; folate/one-carbon constraints) rather than uric acid toxicity per se (vinokurov2023hprt1deficiencyinduces pages 1-2, tsagkaris2023metabolicpatternsin pages 1-2, escuderoferruz2024anewphysiological pages 1-2, sekine2024significanceandamplification pages 2-4).

A 2024 mechanistic advance is that physiologic culture conditions reveal accumulation of ZMP/AICAR in patient fibroblasts (an intermediate in de novo purine synthesis), with plausible downstream signaling effects (e.g., AMPK activation, ADSL inhibition, and mitochondrial oxidative phosphorylation inhibition), and these phenotypes can be masked by supraphysiologic folate levels used in standard media (escuderoferruz2024anewphysiological pages 1-2, escuderoferruz2024anewphysiological media f6714473). A separate 2024 advance clarifies why the CNS is unusually sensitive: human brain tissue shows high HPRT expression and essentially absent xanthine oxidoreductase (XOR), extremely low brain uric acid, and rapid incorporation of hypoxanthine into ATP via salvage—implying that loss of HPRT removes a dominant neuronal route for rapid purine/adenylate replenishment (sekine2024significanceandamplification pages 2-4, sekine2024significanceandamplification pages 4-7).

1) Core pathophysiology

1.1 Key concepts and definitions

  • Purine salvage pathway: Recycling of purine bases (hypoxanthine, guanine) back to nucleotides (IMP, GMP) using PRPP; this reduces energy cost versus de novo synthesis and helps maintain nucleotide pools (camici2023inbornerrorsof pages 7-8, sekine2024significanceandamplification pages 4-7).
  • HGPRT/HPRT (HPRT1): Principal PRPP-dependent salvage enzyme converting hypoxanthine → IMP and guanine → GMP (camici2023inbornerrorsof pages 7-8, sekine2024significanceandamplification pages 2-4).
  • De novo purine synthesis: Energetically intensive pathway generating IMP and downstream adenylate/guanylate nucleotides; requires folate-derived 10-formyltetrahydrofolate at steps catalyzed by GART and ATIC (highlighted in a 2024 pathway schematic) (escuderoferruz2024anewphysiological media f6714473).
  • ZMP/AICAR: A de novo pathway intermediate (AICAR monophosphate; also called ZMP), which can act as an AMP mimetic and influence signaling pathways such as AMPK; its accumulation can indicate altered pathway flux/bottlenecks (escuderoferruz2024anewphysiological pages 1-2, escuderoferruz2024anewphysiological media f6714473).

1.2 Primary pathophysiological mechanisms

(A) Purine salvage failure → hyperuricemia and altered purine pools Loss of HGPRT prevents recycling of hypoxanthine and guanine, contributing to accumulation of bases and increased catabolism to uric acid, alongside increased PRPP and “grossly increased de novo purine synthesis” reported in a 2023 review of inborn purine disorders (camici2023inbornerrorsof pages 8-9). Clinically, xanthine oxidase inhibitors lower urate but do not correct neurologic/behavioral manifestations, supporting urate-independent mechanisms for neurophenotypes (camici2023inbornerrorsof pages 8-9, bairddaniel2023singleelectrodedeepbrain pages 1-2).

(B) De novo pathway acceleration + physiologic folate constraint → ZMP accumulation and stress signaling A 2024 Molecular Medicine study emphasizes that under physiologic folate (e.g., 25 nM folic acid vs ~2200 nM in standard media), LND fibroblasts accumulate ZMP, and ZMP is linked to dysregulation of multiple pathways including AMPK activation, ADSL inhibition, and mitochondrial oxidative phosphorylation inhibition (escuderoferruz2024anewphysiological pages 1-2, escuderoferruz2024anewphysiological media f6714473). Importantly, the study reports that use of a fully physiologic medium (Plasmax-PV) uncovers additional phenotypes including higher glycolytic capacity, increased SLC19A1 (folate carrier) expression, decreased mitochondrial membrane potential, and reduced cell migration, which can be reversed with high folic acid (escuderoferruz2024anewphysiological pages 1-2).

(C) Brain-specific purine economy creates neuronal vulnerability A 2024 JBC study provides a mechanistic rationale for brain vulnerability: human brain has high HPRT, essentially no detectable XOR, and very low uric acid (reported as ~1% of total purines), implying that hypoxanthine is preferentially preserved and routed into salvage rather than oxidized to urate (sekine2024significanceandamplification pages 2-4). In iPSC-derived neurons, labeled hypoxanthine is incorporated into ATP within 5 minutes, indicating that salvage can dominate rapid ATP/purine replenishment; PRPP availability is highlighted as a critical limiter (“hypoxanthine alone has a limited ATP-enhancing effect due to PRPP depletion”), tying pentose phosphate pathway flux to salvage capacity (sekine2024significanceandamplification pages 4-7, sekine2024significanceandamplification pages 12-14).

2) Dysregulated molecular pathways and cellular processes

2.1 Pathways implicated (with mechanistic evidence)

  1. Purine salvage/de novo synthesis balance: PRPP elevation + increased de novo synthesis in HPRT deficiency, shifting flux and creating intermediates such as ZMP (camici2023inbornerrorsof pages 8-9, escuderoferruz2024anewphysiological pages 1-2).
  2. Folate/one-carbon metabolism coupling to purine synthesis: dependence on folate-derived 10-formyl-THF at GART/ATIC steps; physiologic folate reveals metabolic imbalance and adaptive upregulation of folate transport (SLC19A1) (escuderoferruz2024anewphysiological media f6714473, escuderoferruz2024anewphysiological pages 1-2).
  3. AMPK-linked energy stress signaling: ZMP accumulation is linked (in the 2024 LND fibroblast work and its pathway figure) to AMPK activation and downstream mitochondrial effects (escuderoferruz2024anewphysiological media f6714473).
  4. Mitochondrial bioenergetics (Complex I): a 2023 murine neuronal study reports that HPRT1 deficiency inhibits complex I-dependent respiration, increases mitochondrial NADH, reduces mitochondrial membrane potential, and increases ROS; authors interpret this primarily as energy metabolism disruption rather than overt oxidative stress (no glutathione depletion reported in the excerpt) (vinokurov2023hprt1deficiencyinduces pages 1-2).
  5. Dopaminergic developmental programming and basal ganglia circuit function: developmental abnormalities in dopaminergic neuron migration/proliferation and reduced dopaminergic phenotypes have been reported in Hprt-deficient models (camici2023inbornerrorsof pages 8-9, camici2023inbornerrorsof pages 36-37). Network-level alterations are supported by FDG-PET patterns and neuroimaging findings (tsagkaris2023metabolicpatternsin pages 1-2).

2.2 Cellular processes affected

  • Nucleotide homeostasis / adenylate maintenance: rapid salvage of hypoxanthine into ATP in neurons implies HPRT deficiency can compromise acute/chronic maintenance of adenylate pools (sekine2024significanceandamplification pages 4-7).
  • Mitochondrial respiration and membrane potential regulation: decreased mitochondrial potential in LND fibroblasts under physiologic medium; complex I-dependent respiration defects in murine neurons (escuderoferruz2024anewphysiological pages 1-2, vinokurov2023hprt1deficiencyinduces pages 1-2).
  • Cell migration and developmental programs: reduced migration in LND fibroblasts and evidence for altered developmental programming of dopaminergic neurons in models (escuderoferruz2024anewphysiological pages 1-2, camici2023inbornerrorsof pages 8-9).
  • Brain glucose metabolism networks: FDG-PET shows distinctive multi-region hypometabolism pattern for HPRT1 dystonia subgroup (tsagkaris2023metabolicpatternsin pages 1-2).

3) Key molecular players (entities and ontologies)

3.1 Genes/proteins (HGNC; selected relevant GO)

  • HPRT1 (HGNC:5157) – hypoxanthine-guanine phosphoribosyltransferase; central causal gene (camici2023inbornerrorsof pages 7-8, sekine2024significanceandamplification pages 2-4)
  • Example GO processes (conceptual mapping): purine nucleobase salvage; inosine monophosphate biosynthetic process.
  • SLC19A1 (HGNC:1104) – folate transporter (RFC1); increased expression in LND fibroblasts under physiologic medium (escuderoferruz2024anewphysiological pages 1-2)
  • PRPS1/2 (HGNC:9442/9443) – PRPP synthesis (PRPP limitation emphasized for salvage capacity) (sekine2024significanceandamplification pages 12-14)
  • GART (HGNC:4137) and ATIC (HGNC:204) – folate-dependent de novo purine synthesis steps (schematic) (escuderoferruz2024anewphysiological media f6714473)
  • ADSL (HGNC:99) – adenylosuccinate lyase; proposed inhibited by ZMP in LND context (escuderoferruz2024anewphysiological media f6714473)
  • AMPK complex (PRKAA1/2 etc.) – activated by ZMP in the proposed LND pathway schematic (escuderoferruz2024anewphysiological media f6714473)
  • XOR/XDH (xanthine oxidoreductase; gene XDH HGNC:12805) – essentially absent/detectable at very low level in human brain, shaping CNS purine handling (sekine2024significanceandamplification pages 2-4, sekine2024significanceandamplification pages 1-2)

3.2 Chemical entities (CHEBI)

  • Hypoxanthine (CHEBI:17368) – salvage substrate; elevated/handled differently in brain; rapidly incorporated into ATP by salvage in neurons (sekine2024significanceandamplification pages 4-7).
  • Guanine (CHEBI:16235) – salvage substrate (camici2023inbornerrorsof pages 7-8).
  • PRPP (5-phospho-α-D-ribose 1-diphosphate; CHEBI:17111) – required cosubstrate for salvage; depletion limits ATP enhancement by hypoxanthine (sekine2024significanceandamplification pages 12-14).
  • IMP (CHEBI:17514) and GMP (CHEBI:17138) – nucleotide products of salvage (camici2023inbornerrorsof pages 7-8).
  • Uric acid/urate (CHEBI:27226) – end product of purine catabolism; low in brain relative to total purines; corrected by allopurinol but neurologic phenotype persists (sekine2024significanceandamplification pages 2-4, bairddaniel2023singleelectrodedeepbrain pages 1-2).
  • ZMP/AICAR monophosphate (CHEBI:57628) – accumulated in LND fibroblasts in physiologic conditions; linked to AMPK and mitochondrial effects (escuderoferruz2024anewphysiological pages 1-2, escuderoferruz2024anewphysiological media f6714473).
  • Folic acid (CHEBI:27470) and 10-formyl-THF (CHEBI:15636) – key in de novo purine steps (escuderoferruz2024anewphysiological pages 1-2, escuderoferruz2024anewphysiological media f6714473).
  • Allopurinol (CHEBI:46195) – xanthine oxidase inhibitor used clinically (bairddaniel2023singleelectrodedeepbrain pages 1-2, reisz2023redbloodcells pages 5-7).

3.3 Cell types (CL) and anatomical locations (UBERON)

  • Midbrain dopaminergic neurons (CL:0000700) and striatal terminals – implicated in dopaminergic dysfunction and developmental disruption (camici2023inbornerrorsof pages 8-9, alsuwaidi2025onecarbonmetabolismand pages 3-4).
  • Fibroblasts (CL:0000057) – used to reveal physiologic-medium phenotypes including ZMP accumulation and mitochondrial potential reduction (escuderoferruz2024anewphysiological pages 1-2).
  • Erythrocytes (CL:0000232) – multi-omics biomarkers and systemic metabolic effects observed (reisz2023redbloodcells pages 5-7, reisz2023redbloodcells pages 11-14).
  • Basal ganglia / globus pallidus internus (GPi) (UBERON:0002038 / UBERON:0002973) – circuit focus for dystonia and DBS targeting (bairddaniel2023singleelectrodedeepbrain pages 1-2).
  • Thalamus, brainstem, cerebellum, cortex – implicated by FDG-PET hypometabolism patterns (tsagkaris2023metabolicpatternsin pages 1-2).

4) Biological processes (GO-oriented) disrupted (knowledge-base candidates)

The following processes are supported as disrupted/implicated by the evidence base: - Purine nucleobase salvage / purine nucleotide salvage (loss of HGPRT activity) (camici2023inbornerrorsof pages 7-8, sekine2024significanceandamplification pages 2-4) - De novo IMP biosynthetic process / purine ribonucleotide biosynthetic process (compensatory acceleration; ZMP accumulation) (camici2023inbornerrorsof pages 8-9, escuderoferruz2024anewphysiological pages 1-2) - Folate-dependent one-carbon metabolic process (dependency at GART/ATIC; physiologic folate reveals phenotypes; SLC19A1 upregulation) (escuderoferruz2024anewphysiological pages 1-2, escuderoferruz2024anewphysiological media f6714473) - Cellular response to energy starvation / AMPK signaling pathway (ZMP→AMPK activation in pathway schematic) (escuderoferruz2024anewphysiological media f6714473) - Mitochondrial electron transport, NADH to ubiquinone (Complex I) (complex I-dependent respiration inhibition in HPRT1-deficient neurons) (vinokurov2023hprt1deficiencyinduces pages 1-2) - Dopaminergic neuron differentiation/development and axon guidance/migration (abnormal DA neuron development and migration in Hprt-deficient models) (camici2023inbornerrorsof pages 8-9) - Regulation of glucose metabolic process / brain network metabolism (FDG-PET hypometabolism pattern unique to HPRT1 dystonia subgroup) (tsagkaris2023metabolicpatternsin pages 1-2)

5) Cellular components (where key processes occur)

  • Cytosol: HGPRT enzyme activity; PRPP-dependent salvage reactions; de novo purine synthesis steps generating ZMP (camici2023inbornerrorsof pages 7-8, escuderoferruz2024anewphysiological media f6714473).
  • Mitochondria (inner membrane / respiratory chain): complex I-dependent respiration and membrane potential changes implicated in HPRT1 deficiency models (vinokurov2023hprt1deficiencyinduces pages 1-2, escuderoferruz2024anewphysiological pages 1-2).
  • Plasma membrane / transport systems: folate transporter SLC19A1 upregulation and nutrient availability effects under physiologic medium (escuderoferruz2024anewphysiological pages 1-2).
  • Synaptic terminals/circuit nodes (systems-level): striatal terminals and basal ganglia network nodes implicated by dopamine dysfunction and imaging patterns (alsuwaidi2025onecarbonmetabolismand pages 3-4, tsagkaris2023metabolicpatternsin pages 1-2).

6) Disease progression model (sequence of events)

A mechanistically consistent sequence supported by the retrieved evidence is: 1. Genetic trigger: hemizygous loss-of-function variants in HPRT1 → severe HGPRT deficiency (camici2023inbornerrorsof pages 7-8). 2. Immediate metabolic consequences: impaired hypoxanthine/guanine salvage → accumulation of purine bases/PRPP; increased de novo synthesis; increased production of urate (systemically) (camici2023inbornerrorsof pages 8-9, escuderoferruz2024anewphysiological pages 1-2). 3. Brain-specific vulnerability: human brain relies on salvage (high HPRT, absent XOR, rapid salvage incorporation into ATP) → HPRT loss disrupts rapid purine/adenylate maintenance, with PRPP supply as a limiting factor (sekine2024significanceandamplification pages 2-4, sekine2024significanceandamplification pages 4-7, sekine2024significanceandamplification pages 12-14). 4. Cellular stress responses: in physiologic nutrient conditions, de novo pathway intermediate ZMP accumulates and is linked to AMPK/ADSL/mitochondrial effects; fibroblasts show decreased mitochondrial membrane potential and impaired migration (escuderoferruz2024anewphysiological pages 1-2, escuderoferruz2024anewphysiological media f6714473). 5. Neurodevelopmental derailment: Hprt-deficient models exhibit reduced early dopaminergic neurons and abnormal migration, suggesting a critical early developmental window (camici2023inbornerrorsof pages 8-9). 6. Systems/circuit manifestation: basal ganglia network dysfunction (dopamine pathway deficits) yields dystonia and self-injury; FDG-PET patterns show widespread hypometabolism unique to HPRT1 subgroup among pediatric dystonias (tsagkaris2023metabolicpatternsin pages 1-2).

Clinical timing anchors (reported): psychomotor delay may appear at 3–6 months (review excerpt) and motor symptoms/cognitive delay typically present before age 1; self-mutilation onset is often in early childhood (e.g., between ages 1–6) (camici2023inbornerrorsof pages 8-9, bairddaniel2023singleelectrodedeepbrain pages 1-2).

7) Phenotypic manifestations (HP terms) and mechanistic links

  • Hyperuricemia (HP:0002149) / nephrolithiasis (HP:0000787) / gouty arthritis (HP:0001997): explained by increased purine catabolism and urate production due to salvage failure; treated with allopurinol (camici2023inbornerrorsof pages 8-9, bairddaniel2023singleelectrodedeepbrain pages 1-2).
  • Dystonia (HP:0001332) and severe motor disability: linked to basal ganglia circuitry dysfunction and dopaminergic abnormalities; supported by DBS targeting GPi (bairddaniel2023singleelectrodedeepbrain pages 1-2).
  • Self-injurious behavior (HP:0100716) (including compulsive self-mutilation): thought to relate to disrupted dopaminergic circuit development/function in basal ganglia–prefrontal/limbic pathways; DBS reports suggest modifiability via circuit intervention (bairddaniel2023singleelectrodedeepbrain pages 1-2).
  • Intellectual disability / developmental delay (HP:0001249 / HP:0001263): likely linked to early neurodevelopmental programming defects and widespread network-level metabolic abnormalities (camici2023inbornerrorsof pages 8-9, tsagkaris2023metabolicpatternsin pages 1-2).

8) Recent developments (prioritizing 2023–2024)

8.1 Physiologic media reveals masked biochemical/cellular phenotypes (2024)

Escudero-Ferruz et al. (Molecular Medicine; published Jan 2024; https://doi.org/10.1186/s10020-023-00774-8) report that physiologic nutrient conditions uncover LND fibroblast alterations including ZMP accumulation, higher glycolytic capacity, increased SLC19A1, decreased mitochondrial potential, and reduced cell migration, reversible with high folic acid (escuderoferruz2024anewphysiological pages 1-2). A central mechanistic figure explicitly links ZMP to AMPK activation, ADSL inhibition and mitochondrial dysfunction, and highlights folate dependence at GART/ATIC steps (escuderoferruz2024anewphysiological media f6714473).

8.2 Human brain dependence on salvage clarified with tissue + iPSC neuron tracing (2024)

Sekine et al. (J Biol Chem; published Aug 2024; https://doi.org/10.1016/j.jbc.2024.107524) show human brain has high HPRT, minimal XOR, very low uric acid (~1% of total purines), and that iPSC-derived neurons rapidly incorporate hypoxanthine into ATP (detectable within 5 minutes). The work emphasizes PRPP limitation and PPP-mediated amplification of salvage (sekine2024significanceandamplification pages 2-4, sekine2024significanceandamplification pages 4-7, sekine2024significanceandamplification pages 12-14).

8.3 Brain mitochondrial bioenergetics in an Hprt1-deficient mouse model (2023)

Vinokurov et al. (Molecular Neurobiology; published Feb 2023; https://doi.org/10.1007/s12035-023-03266-2) report Hprt1 deficiency inhibits complex I-dependent respiration, increases mitochondrial NADH, reduces membrane potential, and increases ROS; the authors propose disrupted mitochondrial energy metabolism (rather than overt oxidative stress) as a potential trigger for brain pathology (vinokurov2023hprt1deficiencyinduces pages 1-2).

8.4 Imaging biomarkers of dystonia etiology include a distinctive HPRT1 signature (2023)

Tsagkaris et al. (Brain; published Nov 2023; https://doi.org/10.1093/brain/awac439) analyzed FDG-PET in a pediatric dystonia cohort and report that the HPRT1 (Lesch–Nyhan) subgroup “uniquely showed glucose hypometabolism across all nine cerebral regions,” with additional region patterns (temporal, thalamic/brainstem, cerebellar/insula) that differed from other genetic dystonias (tsagkaris2023metabolicpatternsin pages 1-2).

8.5 Translational gene correction by base/prime editing (2023)

Jang et al. (Molecular Therapy – Nucleic Acids; published Mar 2023; https://doi.org/10.1016/j.omtn.2023.02.009) demonstrated modeling and correction of HPRT1 mutations using CRISPR base editors and prime editors. In patient fibroblasts carrying a frameshift (c.333_334ins(A)), an optimized prime editing system achieved ~14% correction and restored HPRT protein/activity as assessed by selection assays and enzymatic readouts (jang2023therapeuticgenecorrection pages 2-4, jang2023therapeuticgenecorrection pages 6-7).

9) Current applications and real-world implementations

9.1 Standard management

  • Urate lowering: allopurinol lowers serum uric acid and reduces stone risk but does not improve movement disorder/neurobehavioral features (bairddaniel2023singleelectrodedeepbrain pages 1-2, reisz2023redbloodcells pages 5-7).
  • Example real-world data: in a 2023 RBC multi-omics study of three affected siblings, serum uric acid at diagnosis was reported ~5–6.5 mg/dL (normal <2–4.5 mg/dL), and allopurinol normalized urate without improving movement disorder (reisz2023redbloodcells pages 5-7).

9.2 Neurosurgical circuit modulation

  • Deep brain stimulation (DBS) of GPi: a 2023 report describes DBS targeting posterolateral GPi in two pediatric patients (ages 6 and 14) with medically resistant disease, with caregiver-reported reductions in dystonia and self-injury (bairddaniel2023singleelectrodedeepbrain pages 1-2). This is consistent with basal ganglia circuit involvement.

9.3 Emerging/experimental causal strategies

  • Genome editing (base/prime editing): in vitro correction of endogenous HPRT1 mutations with functional rescue provides proof-of-principle for causal therapy, but editing efficiency in primary cells remains variable and delivery to relevant brain cell types remains a major translational barrier (jang2023therapeuticgenecorrection pages 6-7, jang2023therapeuticgenecorrection pages 7-8).

10) Expert opinions / analysis (from authoritative sources in the retrieved corpus)

10.1 Urate is not the driver of neurobehavioral disease

Across mechanistic reviews and clinical reports, the consistent observation is that urate-lowering improves gout/nephrolithiasis risk but not neurobehavioral phenotype (camici2023inbornerrorsof pages 8-9, bairddaniel2023singleelectrodedeepbrain pages 1-2). This supports a model in which neurological manifestations are downstream of brain-specific purine handling and neurodevelopmental/circuit mechanisms rather than direct urate toxicity.

10.2 Developmental vs maintenance hypotheses

The evidence base includes strong support for early dopaminergic developmental abnormalities (reduced early DA neurons, abnormal migration) (camici2023inbornerrorsof pages 8-9), while human neuron metabolic tracing highlights ongoing reliance on salvage for rapid ATP/purine replenishment (sekine2024significanceandamplification pages 4-7). Together, these support a hybrid view: early developmental miswiring plus chronic metabolic vulnerability.

10.3 Importance of physiologic model systems

The 2024 physiologic-medium fibroblast study argues that standard media can mask disease-relevant phenotypes (e.g., ZMP accumulation, mitochondrial potential changes), implying that future mechanistic and therapeutic screens should use physiologic nutrient conditions for metabolic diseases like LND (escuderoferruz2024anewphysiological pages 1-2).

11) Relevant statistics and quantitative data (recent studies)

  • Incidence estimate: ~1 in 380,000 live births (clinical report summary) (bairddaniel2023singleelectrodedeepbrain pages 1-2).
  • FDG-PET cohort: 267 children scanned; 240 analyzed (no gross anatomic abnormality); patterns examined in 144/240 (60%) across 10 dystonia etiologies; HPRT1 showed unique hypometabolism across all nine cerebral regions (tsagkaris2023metabolicpatternsin pages 1-2).
  • Brain biochemistry (human tissue): total extracted purines ~2000 pmol/mg tissue; uric acid ~1% of total purines (sekine2024significanceandamplification pages 2-4).
  • Neuronal salvage kinetics: hypoxanthine incorporation into ATP detectable within 5 min in iPSC-derived neurons (sekine2024significanceandamplification pages 4-7).
  • Serum urate (example LNS family): ~5–6.5 mg/dL at diagnosis in three affected siblings; allopurinol normalized urate but not movement disorder (reisz2023redbloodcells pages 5-7).
  • RBC omics statistics (2023): 103/257 lipids differentially abundant (p<0.05) and 147 RBC proteins significantly altered (p<0.05) in a small family cohort study (reisz2023redbloodcells pages 11-14).
  • Gene correction efficiency: prime editing improved to ~14% in patient fibroblasts with functional rescue (jang2023therapeuticgenecorrection pages 6-7).

12) Evidence items (knowledge-base ready; with source links)

Note on PMIDs: The retrieved tool excerpts did not contain explicit PMID strings, so this report provides DOIs/URLs and publication dates as primary identifiers.

  1. Escudero-Ferruz P, et al. Molecular Medicine. Jan 2024. “A new physiological medium uncovers biochemical and cellular alterations in Lesch-Nyhan disease fibroblasts.” https://doi.org/10.1186/s10020-023-00774-8 (escuderoferruz2024anewphysiological pages 1-2)
  2. Sekine M, et al. Journal of Biological Chemistry. Aug 2024. “Significance and amplification methods of the purine salvage pathway in human brain cells.” https://doi.org/10.1016/j.jbc.2024.107524 (sekine2024significanceandamplification pages 2-4)
  3. Vinokurov AY, et al. Molecular Neurobiology. Feb 2023. “HPRT1 Deficiency Induces Alteration of Mitochondrial Energy Metabolism in the Brain.” https://doi.org/10.1007/s12035-023-03266-2 (vinokurov2023hprt1deficiencyinduces pages 1-2)
  4. Tsagkaris S, et al. Brain. Nov 2023. “Metabolic patterns in brain 18F-fluorodeoxyglucose PET relate to aetiology in paediatric dystonia.” https://doi.org/10.1093/brain/awac439 (tsagkaris2023metabolicpatternsin pages 1-2)
  5. Jang G, et al. Molecular Therapy – Nucleic Acids. Mar 2023. “Therapeutic gene correction for Lesch-Nyhan syndrome using CRISPR-mediated base and prime editing.” https://doi.org/10.1016/j.omtn.2023.02.009 (jang2023therapeuticgenecorrection pages 2-4)
  6. Reisz JA, et al. Antioxidants. Aug 2023. “Red Blood Cells from Individuals with Lesch–Nyhan Syndrome: Multi-Omics Insights…” https://doi.org/10.3390/antiox12091699 (reisz2023redbloodcells pages 5-7)

13) Curated mechanism summary table

The following table summarizes cross-scale mechanisms and is intended for direct knowledge-base ingestion.

Mechanistic layer Key findings Key molecules/metabolites Primary cell types/tissues Evidence (paper + year + URL) Notes/quantitative data
Genetic Lesch–Nyhan syndrome results from loss-of-function variants in HPRT1, causing near-complete deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT/HPRT), the key PRPP-dependent salvage enzyme converting hypoxanthine and guanine to IMP and GMP. Severe classic disease is associated with very low residual activity. HPRT1/HGPRT, PRPP, hypoxanthine, guanine, IMP, GMP Brain (high HPRT expression), erythrocytes, fibroblasts Camici et al., 2023, https://doi.org/10.3390/metabo13070787 (camici2023inbornerrorsof pages 7-8); Alsuwaidi & Ernst, 2025, https://doi.org/10.1159/000549247 (alsuwaidi2025onecarbonmetabolismand pages 1-2, alsuwaidi2025onecarbonmetabolismand pages 2-3) >95% activity loss linked to classic LND in review excerpt; >600 HPRT mutations noted in review literature (camici2023inbornerrorsof pages 7-8, alsuwaidi2025onecarbonmetabolismand pages 2-3)
Metabolic Salvage failure causes accumulation of unrecycled purine bases and PRPP, accelerates de novo purine synthesis, and increases uric acid production; xanthine oxidase inhibitors lower urate but do not correct neurological disease. PRPP, hypoxanthine, xanthine, uric acid, IMP, GMP Liver/systemic purine metabolism; fibroblasts; brain Escudero-Ferruz et al., 2024, https://doi.org/10.1186/s10020-023-00774-8 (escuderoferruz2024anewphysiological pages 1-2); Camici et al., 2023, https://doi.org/10.3390/metabo13070787 (camici2023inbornerrorsof pages 8-9); Vinokurov et al., 2023, https://doi.org/10.1007/s12035-023-03266-2 (vinokurov2023hprt1deficiencyinduces pages 1-2) Hyperuricemia may be evident from birth; neurological features persist despite urate lowering (camici2023inbornerrorsof pages 8-9, vinokurov2023hprt1deficiencyinduces pages 1-2)
Metabolic Under physiological folate conditions, HPRT-deficient fibroblasts accumulate ZMP/AICAR, revealing a de novo purine bottleneck not seen in standard high-folate media. ZMP/AICAR, folic acid, 10-formyl-THF Patient fibroblasts Escudero-Ferruz et al., 2024, https://doi.org/10.1186/s10020-023-00774-8 (escuderoferruz2024anewphysiological pages 1-2, escuderoferruz2024anewphysiological media f6714473) Physiological folic acid 25 nM vs ~2200 nM in standard media highlighted in pathway figure summary (escuderoferruz2024anewphysiological pages 1-2, escuderoferruz2024anewphysiological media f6714473)
Signaling ZMP is linked to AMPK activation, ADSL inhibition, and inhibition of mitochondrial oxidative phosphorylation, connecting purine disequilibrium to stress-response signaling and bioenergetic dysfunction. ZMP/AICAR, AMPK, ADSL Fibroblasts; likely broader relevance to neurons Escudero-Ferruz et al., 2024, https://doi.org/10.1186/s10020-023-00774-8 (escuderoferruz2024anewphysiological pages 1-2, escuderoferruz2024anewphysiological media f6714473) Supported by pathway schematic and physiological-medium experiments; high folate reversibility suggests nutrient-sensitive signaling effects (escuderoferruz2024anewphysiological pages 1-2, escuderoferruz2024anewphysiological media f6714473)
One-carbon / folate metabolism Loss of salvage creates greater demand on de novo purine synthesis, increasing dependence on one-carbon metabolism and folate-derived 10-formyl-THF at the GART and ATIC steps; HPRT-deficient cells upregulate folate transport and may reroute one-carbon flux away from other pathways. 10-formyl-THF, GART, ATIC, SLC19A1, serine/OCM intermediates Fibroblasts; midbrain dopaminergic cells (hypothesized vulnerable cell type) Escudero-Ferruz et al., 2024, https://doi.org/10.1186/s10020-023-00774-8 (escuderoferruz2024anewphysiological pages 1-2); Alsuwaidi & Ernst, 2025, https://doi.org/10.1159/000549247 (alsuwaidi2025onecarbonmetabolismand pages 3-4, alsuwaidi2025onecarbonmetabolismand pages 1-2) Increased SLC19A1 expression and reversibility with high folate reported in fibroblasts; OCM rerouting proposed as a disease mechanism for DA neurons (escuderoferruz2024anewphysiological pages 1-2, alsuwaidi2025onecarbonmetabolismand pages 3-4)
Cellular / bioenergetic HPRT1 deficiency impairs complex I-dependent mitochondrial respiration, increases mitochondrial NADH, lowers mitochondrial membrane potential, and elevates mitochondrial/cytosolic ROS; in murine neurons this was interpreted as energy-metabolism disruption more than overt oxidative damage. Complex I, NADH, ROS, glutathione, mitochondrial membrane potential Murine cortical and midbrain neurons; fibroblasts Vinokurov et al., 2023, https://doi.org/10.1007/s12035-023-03266-2 (vinokurov2023hprt1deficiencyinduces pages 1-2); Escudero-Ferruz et al., 2024, https://doi.org/10.1186/s10020-023-00774-8 (escuderoferruz2024anewphysiological pages 1-2) ROS increased without GSH depletion in neuronal study; fibroblasts showed decreased mitochondrial potential and higher glycolytic capacity (vinokurov2023hprt1deficiencyinduces pages 1-2, escuderoferruz2024anewphysiological pages 1-2)
Cellular / motility HPRT-deficient cells show reduced migration and broader developmental-gene dysregulation, supporting a developmental component rather than solely toxic metabolite accumulation. Homeobox genes, developmental programs, folate transporter SLC19A1 Fibroblasts; pluripotent/neuroectodermal cells Escudero-Ferruz et al., 2024, https://doi.org/10.1186/s10020-023-00774-8 (escuderoferruz2024anewphysiological pages 1-2); Torres et al., 2025, https://doi.org/10.3390/cells14141105 (from search result summary, not cited here) Reduced migration in physiological medium; development and nervous-system GO categories highlighted in related stem-cell work, but table relies only on cited context IDs for mechanistic claims (escuderoferruz2024anewphysiological pages 1-2)
Brain purine economy Human brain is unusually dependent on salvage: HPRT is high, XOR is essentially absent, brain uric acid is very low, and hypoxanthine is preferentially routed into IMP/ATP rather than xanthine/urate. This helps explain neuronal sensitivity to HPRT loss. HPRT, XOR, hypoxanthine, PRPP, IMP, ATP, uric acid Human brain tissue; iPSC-derived neurons Sekine et al., 2024, https://doi.org/10.1016/j.jbc.2024.107524 (sekine2024significanceandamplification pages 2-4, sekine2024significanceandamplification pages 1-2, sekine2024significanceandamplification pages 4-7, sekine2024significanceandamplification pages 12-14) Uric acid ~1% of total purines in brain; total purines ~2000 pmol/mg tissue; labeled hypoxanthine incorporated into ATP within 5 min in iPSC-derived neurons (sekine2024significanceandamplification pages 2-4, sekine2024significanceandamplification pages 4-7)
Neurodevelopmental Evidence supports an early developmental defect of dopaminergic neurons: reduced early DA neurons, abnormal migration/radial-glia scaffolds, disorganized innervation, and altered expression of developmental regulators and receptors in HPRT-deficient models. Dopamine, TH, AADC, Wnt4, Wnt11, LMX1B, DRD1, ADORA2A, ADORA2B, 5-HTR7 Midbrain dopaminergic neurons, basal ganglia/striatum Camici et al., 2023, https://doi.org/10.3390/metabo13070787 (camici2023inbornerrorsof pages 8-9, camici2023inbornerrorsof pages 36-37); Mileti & Baleja, 2025, https://doi.org/10.3390/molecules30040839 (mileti2025theroleof pages 15-16, mileti2025theroleof pages 13-15) CSF hypoxanthine reported ~4-fold above controls in review excerpt; HPRT-KO embryos/mice show developmental DA abnormalities (mileti2025theroleof pages 13-15, camici2023inbornerrorsof pages 8-9)
Neurochemical Basal ganglia dopamine signaling is markedly deficient, with depletion of dopamine release/synthesis markers and compensatory receptor-level changes; dopamine deficiency is focal rather than due to gross global brain malformation. Dopamine, TH, AADC, DOPAC, HVA, dopamine transporters, BH4/GTP Striatal terminals, substantia nigra, basal ganglia Vinokurov et al., 2023, https://doi.org/10.1007/s12035-023-03266-2 (vinokurov2023hprt1deficiencyinduces pages 1-2); Mileti & Baleja, 2025, https://doi.org/10.3390/molecules30040839 (mileti2025theroleof pages 13-15); Alsuwaidi & Ernst, 2025, https://doi.org/10.1159/000549247 (alsuwaidi2025onecarbonmetabolismand pages 3-4) Review excerpts cite 70–90% dopamine reduction in basal ganglia; PET evidence indicates loss of dopamine release and depletion of dopamine-synthesis enzymes without cell loss in some studies (vinokurov2023hprt1deficiencyinduces pages 1-2, alsuwaidi2025onecarbonmetabolismand pages 3-4)
Systems / neurocircuit Imaging supports network-level disease: white-matter and regional brain-volume losses, especially in basal ganglia/frontotemporal-limbic regions, plus characteristic metabolic network abnormalities on FDG-PET. Glucose metabolism network changes; white matter connectivity Basal ganglia, thalamus, brainstem, cerebellum, cortex Tsagkaris et al., 2023, https://doi.org/10.1093/brain/awac439 (tsagkaris2023metabolicpatternsin pages 1-2); Mileti & Baleja, 2025, https://doi.org/10.3390/molecules30040839 (mileti2025theroleof pages 15-16) FDG-PET: HPRT1 cases uniquely showed hypometabolism across all 9 cerebral regions in the pediatric dystonia cohort; classic LND review excerpt cites white matter ↓~26% and gray matter ↓~17% vs controls (tsagkaris2023metabolicpatternsin pages 1-2, mileti2025theroleof pages 15-16)
Clinical progression Sequence is consistent with: congenital salvage defect → hyperuricemia/oxypurine excess and altered purine flux → early neurodevelopmental DA-circuit abnormalities → infantile motor delay/dystonia → later self-injurious behavior. Hypoxanthine, xanthine, uric acid, dopamine-related pathways Kidney/systemic metabolism; basal ganglia circuits Camici et al., 2023, https://doi.org/10.3390/metabo13070787 (camici2023inbornerrorsof pages 8-9, camici2023inbornerrorsof pages 7-8); Alsuwaidi & Ernst, 2025, https://doi.org/10.1159/000549247 (alsuwaidi2025onecarbonmetabolismand pages 3-4); Baird-Daniel et al., 2023, https://doi.org/10.7759/cureus.37070 (bairddaniel2023singleelectrodedeepbrain pages 1-2) Psychomotor delay often appears by 3–6 months; dystonia/signs between 4–12 months; self-injury usually begins after infancy, median ~2 years, often age 1–6 years (camici2023inbornerrorsof pages 8-9, alsuwaidi2025onecarbonmetabolismand pages 3-4, bairddaniel2023singleelectrodedeepbrain pages 1-2)
Real-world implementation / translational Current therapy effectively treats urate overproduction (allopurinol) but not core neurobehavioral disease; DBS of the GPi can reduce dystonia/self-injury in refractory cases; gene correction with CRISPR base/prime editing restores HPRT function in human cells, supporting future causal therapy. Allopurinol, GPi DBS, CRISPR base editors, prime editors, HPRT protein/IMP assay Patients with LND; patient fibroblasts; HAP1/HEK293T cells Baird-Daniel et al., 2023, https://doi.org/10.7759/cureus.37070 (bairddaniel2023singleelectrodedeepbrain pages 1-2); Jang et al., 2023, https://doi.org/10.1016/j.omtn.2023.02.009 (jang2023therapeuticgenecorrection pages 1-2, jang2023therapeuticgenecorrection pages 2-4, jang2023therapeuticgenecorrection pages 6-7, jang2023therapeuticgenecorrection pages 4-6, jang2023therapeuticgenecorrection pages 7-8) DBS report adds 2 pediatric cases to prior literature of 14 cases; prime editing in patient fibroblasts improved to ~14% with restored HPRT protein/function, while HEK293T correction reached ~46.7–50% in optimized settings (bairddaniel2023singleelectrodedeepbrain pages 1-2, jang2023therapeuticgenecorrection pages 6-7, jang2023therapeuticgenecorrection pages 4-6, jang2023therapeuticgenecorrection pages 7-8)
Peripheral omics / biomarker layer RBC multi-omics shows systemic consequences of HPRT deficiency: sharp loss of HPRT protein/GMP, altered glycolysis, membrane lipids, trace metals, redox/coagulation proteins, and incomplete biochemical normalization with allopurinol. HPRT protein, GMP, hypoxanthine, inosine, PEP, pyruvate, PCs, SMs, acylcarnitines, Fe/Zn/Se/K Red blood cells Reisz et al., 2023, https://doi.org/10.3390/antiox12091699 (reisz2023redbloodcells pages 5-7, reisz2023redbloodcells pages 7-10, reisz2023redbloodcells pages 1-2, reisz2023redbloodcells pages 11-14) 3 affected boys with novel p.S162N variant; serum uric acid ~5–6.5 mg/dL at diagnosis; 103/257 lipids and 147 proteins significantly altered; allopurinol normalized uric acid but incompletely reversed omics phenotype (reisz2023redbloodcells pages 5-7, reisz2023redbloodcells pages 11-14)

Table: This table condenses the provided evidence on Lesch–Nyhan syndrome from gene defect to metabolic, signaling, cellular, and neurocircuit consequences. It also highlights quantitative findings and current translational applications supported by the cited context IDs.

14) Key mechanistic schematic (figure evidence)

A pathway figure from the 2024 physiologic-medium study explicitly depicts HGPRT deficiency, ZMP accumulation, AMPK/ADSL/mitochondrial consequences, and folate dependence (escuderoferruz2024anewphysiological media f6714473).

Direct quote highlights (from retrieved evidence)

  • FDG-PET signature: HPRT1 (Lesch–Nyhan) “uniquely showed glucose hypometabolism across all nine cerebral regions” in a pediatric dystonia FDG-PET cohort study (Tsagkaris et al., 2023; https://doi.org/10.1093/brain/awac439) (tsagkaris2023metabolicpatternsin pages 1-2).
  • Brain urate scarcity: human brain uric acid reported as “1% of total purines” with HPRT high and XOR essentially absent (Sekine et al., 2024; https://doi.org/10.1016/j.jbc.2024.107524) (sekine2024significanceandamplification pages 2-4).

Practical implications for therapeutic development

  1. Modeling conditions matter: physiologic nutrient/folate conditions can reveal disease-relevant phenotypes and potential intervention points (folate sensitivity, AMPK-linked pathways) that may be missed in standard culture (escuderoferruz2024anewphysiological pages 1-2, escuderoferruz2024anewphysiological media f6714473).
  2. CNS-focused strategies must address salvage/energy demands: human neuronal reliance on rapid salvage suggests that interventions increasing PRPP availability or modulating salvage flux could be mechanistically relevant, but this remains preclinical (sekine2024significanceandamplification pages 4-7, sekine2024significanceandamplification pages 12-14).
  3. Circuit-level interventions can be beneficial despite metabolic etiology: GPi DBS can reduce dystonia/self-injury in refractory cases, consistent with basal ganglia network dysfunction (bairddaniel2023singleelectrodedeepbrain pages 1-2).
  4. Causal therapies are emerging but early: CRISPR base/prime editing can restore HPRT function in patient fibroblasts; translating to brain requires improved delivery, editing efficiency, and safety evaluation (jang2023therapeuticgenecorrection pages 6-7, jang2023therapeuticgenecorrection pages 7-8).

References

  1. (camici2023inbornerrorsof pages 7-8): Marcella Camici, Mercedes Garcia-Gil, Simone Allegrini, Rossana Pesi, Giulia Bernardini, Vanna Micheli, and Maria Grazia Tozzi. Inborn errors of purine salvage and catabolism. Metabolites, 13:787, Jun 2023. URL: https://doi.org/10.3390/metabo13070787, doi:10.3390/metabo13070787. This article has 21 citations.

  2. (camici2023inbornerrorsof pages 8-9): Marcella Camici, Mercedes Garcia-Gil, Simone Allegrini, Rossana Pesi, Giulia Bernardini, Vanna Micheli, and Maria Grazia Tozzi. Inborn errors of purine salvage and catabolism. Metabolites, 13:787, Jun 2023. URL: https://doi.org/10.3390/metabo13070787, doi:10.3390/metabo13070787. This article has 21 citations.

  3. (bairddaniel2023singleelectrodedeepbrain pages 1-2): Eliza Baird-Daniel, Adam Glaser, Scott Boop, Sharon Durfy, and Jason S Hauptman. Single-electrode deep brain stimulation of bilateral posterolateral globus pallidus internus in patients with medically resistant lesch-nyhan syndrome. Cureus, Apr 2023. URL: https://doi.org/10.7759/cureus.37070, doi:10.7759/cureus.37070. This article has 1 citations.

  4. (vinokurov2023hprt1deficiencyinduces pages 1-2): Andrey Y. Vinokurov, Vladislav O. Soldatov, Evgenia S. Seregina, Angelina I. Dolgikh, Pavel A. Tagunov, Andrey V. Dunaev, Marina Y. Skorkina, Alexey V. Deykin, and Andrey Y. Abramov. Hprt1 deficiency induces alteration of mitochondrial energy metabolism in the brain. Molecular Neurobiology, 60:3147-3157, Feb 2023. URL: https://doi.org/10.1007/s12035-023-03266-2, doi:10.1007/s12035-023-03266-2. This article has 23 citations and is from a peer-reviewed journal.

  5. (tsagkaris2023metabolicpatternsin pages 1-2): Stavros Tsagkaris, Eric K C Yau, Verity McClelland, Apostolos Papandreou, Ata Siddiqui, Daniel E Lumsden, Margaret Kaminska, Eric Guedj, Alexander Hammers, and Jean-Pierre Lin. Metabolic patterns in brain 18f-fluorodeoxyglucose pet relate to aetiology in paediatric dystonia. Brain, 146:2512-2523, Nov 2023. URL: https://doi.org/10.1093/brain/awac439, doi:10.1093/brain/awac439. This article has 12 citations and is from a highest quality peer-reviewed journal.

  6. (escuderoferruz2024anewphysiological pages 1-2): Paula Escudero-Ferruz, Neus Ontiveros, Claudia Cano-Estrada, Diane J. Sutcliffe, H. A. Jinnah, Rosa J. Torres, and José M. López. A new physiological medium uncovers biochemical and cellular alterations in lesch-nyhan disease fibroblasts. Molecular Medicine, Jan 2024. URL: https://doi.org/10.1186/s10020-023-00774-8, doi:10.1186/s10020-023-00774-8. This article has 11 citations and is from a peer-reviewed journal.

  7. (sekine2024significanceandamplification pages 2-4): Mai Sekine, Megumi Fujiwara, Ken Okamoto, Kimiyoshi Ichida, Koji Nagata, Russ Hille, and Takeshi Nishino. Significance and amplification methods of the purine salvage pathway in human brain cells. Journal of Biological Chemistry, 300:107524, Aug 2024. URL: https://doi.org/10.1016/j.jbc.2024.107524, doi:10.1016/j.jbc.2024.107524. This article has 19 citations and is from a domain leading peer-reviewed journal.

  8. (escuderoferruz2024anewphysiological media f6714473): Paula Escudero-Ferruz, Neus Ontiveros, Claudia Cano-Estrada, Diane J. Sutcliffe, H. A. Jinnah, Rosa J. Torres, and José M. López. A new physiological medium uncovers biochemical and cellular alterations in lesch-nyhan disease fibroblasts. Molecular Medicine, Jan 2024. URL: https://doi.org/10.1186/s10020-023-00774-8, doi:10.1186/s10020-023-00774-8. This article has 11 citations and is from a peer-reviewed journal.

  9. (sekine2024significanceandamplification pages 4-7): Mai Sekine, Megumi Fujiwara, Ken Okamoto, Kimiyoshi Ichida, Koji Nagata, Russ Hille, and Takeshi Nishino. Significance and amplification methods of the purine salvage pathway in human brain cells. Journal of Biological Chemistry, 300:107524, Aug 2024. URL: https://doi.org/10.1016/j.jbc.2024.107524, doi:10.1016/j.jbc.2024.107524. This article has 19 citations and is from a domain leading peer-reviewed journal.

  10. (sekine2024significanceandamplification pages 12-14): Mai Sekine, Megumi Fujiwara, Ken Okamoto, Kimiyoshi Ichida, Koji Nagata, Russ Hille, and Takeshi Nishino. Significance and amplification methods of the purine salvage pathway in human brain cells. Journal of Biological Chemistry, 300:107524, Aug 2024. URL: https://doi.org/10.1016/j.jbc.2024.107524, doi:10.1016/j.jbc.2024.107524. This article has 19 citations and is from a domain leading peer-reviewed journal.

  11. (camici2023inbornerrorsof pages 36-37): Marcella Camici, Mercedes Garcia-Gil, Simone Allegrini, Rossana Pesi, Giulia Bernardini, Vanna Micheli, and Maria Grazia Tozzi. Inborn errors of purine salvage and catabolism. Metabolites, 13:787, Jun 2023. URL: https://doi.org/10.3390/metabo13070787, doi:10.3390/metabo13070787. This article has 21 citations.

  12. (sekine2024significanceandamplification pages 1-2): Mai Sekine, Megumi Fujiwara, Ken Okamoto, Kimiyoshi Ichida, Koji Nagata, Russ Hille, and Takeshi Nishino. Significance and amplification methods of the purine salvage pathway in human brain cells. Journal of Biological Chemistry, 300:107524, Aug 2024. URL: https://doi.org/10.1016/j.jbc.2024.107524, doi:10.1016/j.jbc.2024.107524. This article has 19 citations and is from a domain leading peer-reviewed journal.

  13. (reisz2023redbloodcells pages 5-7): Julie A. Reisz, Monika Dzieciatkowska, Daniel Stephenson, Fabia Gamboni, D. Holmes Morton, and Angelo D’Alessandro. Red blood cells from individuals with lesch–nyhan syndrome: multi-omics insights into a novel s162n mutation causing hypoxanthine-guanine phosphoribosyltransferase deficiency. Antioxidants, 12:1699, Aug 2023. URL: https://doi.org/10.3390/antiox12091699, doi:10.3390/antiox12091699. This article has 16 citations.

  14. (alsuwaidi2025onecarbonmetabolismand pages 3-4): Shaima Alsuwaidi and Carl Ernst. One-carbon metabolism and midbrain dopaminergic cells in lesch-nyhan disease. Molecular Syndromology, pages 1-14, Nov 2025. URL: https://doi.org/10.1159/000549247, doi:10.1159/000549247. This article has 0 citations and is from a peer-reviewed journal.

  15. (reisz2023redbloodcells pages 11-14): Julie A. Reisz, Monika Dzieciatkowska, Daniel Stephenson, Fabia Gamboni, D. Holmes Morton, and Angelo D’Alessandro. Red blood cells from individuals with lesch–nyhan syndrome: multi-omics insights into a novel s162n mutation causing hypoxanthine-guanine phosphoribosyltransferase deficiency. Antioxidants, 12:1699, Aug 2023. URL: https://doi.org/10.3390/antiox12091699, doi:10.3390/antiox12091699. This article has 16 citations.

  16. (jang2023therapeuticgenecorrection pages 2-4): Gayoung Jang, Ha Rim Shin, Hyo-Sang Do, Jiyeon Kweon, Soojin Hwang, Soyoung Kim, Sun Hee Heo, Yongsub Kim, and Beom Hee Lee. Therapeutic gene correction for lesch-nyhan syndrome using crispr-mediated base and prime editing. Molecular Therapy - Nucleic Acids, 31:586-595, Mar 2023. URL: https://doi.org/10.1016/j.omtn.2023.02.009, doi:10.1016/j.omtn.2023.02.009. This article has 19 citations.

  17. (jang2023therapeuticgenecorrection pages 6-7): Gayoung Jang, Ha Rim Shin, Hyo-Sang Do, Jiyeon Kweon, Soojin Hwang, Soyoung Kim, Sun Hee Heo, Yongsub Kim, and Beom Hee Lee. Therapeutic gene correction for lesch-nyhan syndrome using crispr-mediated base and prime editing. Molecular Therapy - Nucleic Acids, 31:586-595, Mar 2023. URL: https://doi.org/10.1016/j.omtn.2023.02.009, doi:10.1016/j.omtn.2023.02.009. This article has 19 citations.

  18. (jang2023therapeuticgenecorrection pages 7-8): Gayoung Jang, Ha Rim Shin, Hyo-Sang Do, Jiyeon Kweon, Soojin Hwang, Soyoung Kim, Sun Hee Heo, Yongsub Kim, and Beom Hee Lee. Therapeutic gene correction for lesch-nyhan syndrome using crispr-mediated base and prime editing. Molecular Therapy - Nucleic Acids, 31:586-595, Mar 2023. URL: https://doi.org/10.1016/j.omtn.2023.02.009, doi:10.1016/j.omtn.2023.02.009. This article has 19 citations.

  19. (alsuwaidi2025onecarbonmetabolismand pages 1-2): Shaima Alsuwaidi and Carl Ernst. One-carbon metabolism and midbrain dopaminergic cells in lesch-nyhan disease. Molecular Syndromology, pages 1-14, Nov 2025. URL: https://doi.org/10.1159/000549247, doi:10.1159/000549247. This article has 0 citations and is from a peer-reviewed journal.

  20. (alsuwaidi2025onecarbonmetabolismand pages 2-3): Shaima Alsuwaidi and Carl Ernst. One-carbon metabolism and midbrain dopaminergic cells in lesch-nyhan disease. Molecular Syndromology, pages 1-14, Nov 2025. URL: https://doi.org/10.1159/000549247, doi:10.1159/000549247. This article has 0 citations and is from a peer-reviewed journal.

  21. (mileti2025theroleof pages 15-16): Lauren N. Mileti and James D. Baleja. The role of purine metabolism and uric acid in postnatal neurologic development. Molecules, 30:839, Feb 2025. URL: https://doi.org/10.3390/molecules30040839, doi:10.3390/molecules30040839. This article has 15 citations.

  22. (mileti2025theroleof pages 13-15): Lauren N. Mileti and James D. Baleja. The role of purine metabolism and uric acid in postnatal neurologic development. Molecules, 30:839, Feb 2025. URL: https://doi.org/10.3390/molecules30040839, doi:10.3390/molecules30040839. This article has 15 citations.

  23. (jang2023therapeuticgenecorrection pages 1-2): Gayoung Jang, Ha Rim Shin, Hyo-Sang Do, Jiyeon Kweon, Soojin Hwang, Soyoung Kim, Sun Hee Heo, Yongsub Kim, and Beom Hee Lee. Therapeutic gene correction for lesch-nyhan syndrome using crispr-mediated base and prime editing. Molecular Therapy - Nucleic Acids, 31:586-595, Mar 2023. URL: https://doi.org/10.1016/j.omtn.2023.02.009, doi:10.1016/j.omtn.2023.02.009. This article has 19 citations.

  24. (jang2023therapeuticgenecorrection pages 4-6): Gayoung Jang, Ha Rim Shin, Hyo-Sang Do, Jiyeon Kweon, Soojin Hwang, Soyoung Kim, Sun Hee Heo, Yongsub Kim, and Beom Hee Lee. Therapeutic gene correction for lesch-nyhan syndrome using crispr-mediated base and prime editing. Molecular Therapy - Nucleic Acids, 31:586-595, Mar 2023. URL: https://doi.org/10.1016/j.omtn.2023.02.009, doi:10.1016/j.omtn.2023.02.009. This article has 19 citations.

  25. (reisz2023redbloodcells pages 7-10): Julie A. Reisz, Monika Dzieciatkowska, Daniel Stephenson, Fabia Gamboni, D. Holmes Morton, and Angelo D’Alessandro. Red blood cells from individuals with lesch–nyhan syndrome: multi-omics insights into a novel s162n mutation causing hypoxanthine-guanine phosphoribosyltransferase deficiency. Antioxidants, 12:1699, Aug 2023. URL: https://doi.org/10.3390/antiox12091699, doi:10.3390/antiox12091699. This article has 16 citations.

  26. (reisz2023redbloodcells pages 1-2): Julie A. Reisz, Monika Dzieciatkowska, Daniel Stephenson, Fabia Gamboni, D. Holmes Morton, and Angelo D’Alessandro. Red blood cells from individuals with lesch–nyhan syndrome: multi-omics insights into a novel s162n mutation causing hypoxanthine-guanine phosphoribosyltransferase deficiency. Antioxidants, 12:1699, Aug 2023. URL: https://doi.org/10.3390/antiox12091699, doi:10.3390/antiox12091699. This article has 16 citations.